Antigen-specific Effector CD8 T Cells Regulate Allergic Responses via IFN-y and Dendritic Cell Function by TANG YAFANG
 ANTIGEN-SPECIFIC EFFECTOR CD8 T CELLS REGULATE 






BSc (Honors), NUS 
 
 




NUS GRADUATE SCHOOL FOR INTEGRATIVE SCIENCES 
AND ENGINEERING 






While the pivotal role of CD4 T cells has been extensively studied in allergic asthma, 
the role of CD8 T cells remains controversial. Previous studies have shown that CD8 
T cells can both prevent and cause allergic responses. However, the underlying 
mechanisms remain to be elucidated. In this study, we aim to investigate the potential 
of CD8 T cells with different IFN-γ expressions to modulate the elicitation of allergic 
inflammation following ovalbumin (OVA) challenge and investigate the underlying 
mechanisms. To study the role of IFN-γ in the effect of CD8 T cells, effector CD8 T 
cells from OT-I and IFN-γ
-/-
OT-I mice were transferred to OVA-sensitized mice one 
day before the 3 consecutive challenges. The effect on lung dendritic cells (DCs) 
exerted by CD8 T cells was studied with ex vivo culture of sorted DCs from treatment 
mice with either naïve or antigen-experienced CD4 T cells. We found that effector 
OT-I, but not IFN-γ
-/-
OT-I CD8 T cells attenuated eosinophilia and mucus secretion 
in the lungs of sensitized mice in an antigen-specific manner. Effector IFN-γ
-/-
OT-I 
CD8 T cells displayed a Tc2/Tc17-biased phenotype with weaker cytotoxicity and 
were able to both induce and exacerbate eosinophilia as well as neutrophilia. OT-I 




 DCs to both prime the 
differentiation of naïve CD4 T cells toward a Th1 phenotype and enhance IFN-γ 
production by antigen-experienced lung CD4 T cells. In conclusion, effector CD8 T 
cells attenuate pulmonary inflammation and alter the ability of DCs within the 
allergic lung to polarize T cells to a Th1 phenotype during a Th2 response. In the 
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Asthma is a reversible airway obstructive disease with high heterogeneity.   It is 
characterized by chronic airway inflammation, airway hyper-responsiveness (AHR) 
and with symptoms of recurrent coughing, wheezing, chest tightness and shortness of 
breath  (Kim et al., 2010). Asthma is not a clearly-defined disease but rather a 
collective term for diseases with similar manifestations and the severity of which is 
determined by multiple environmental factors and more than 100 susceptibility genes. 
Long after its first recognition by Hippocrates, a Greek physician, it was considered 
as one of the psychosomatic illnesses for centuries until John C. Thorowgood 
explained its pathophysiology in 1873 (Thorowgood, 1873). From then on, the 
mechanisms, diagnosis and treatment of asthma started to be investigated and 
explored.  
 
Clinically, asthma is usually classified according to the frequency and severity of 
symptoms, forced expiratory volume in 1 second (FEV1) and peak expiratory flow 
rate. However, in asthma research, especially those using animal models, asthma is 
more commonly classified based on the origin and cause of the disease. Allergic 
asthma, the more common form of asthma, is differentiated from non-allergic asthma 
which normally shows negative skin test results to common aeroallergens (Romanet-




Manent et al., 2002).  Allergic asthma is more widely investigated and will be the 
focus of our study. 
 
1.1.1 Asthma prevalence and economic burden 
 
Over the past few decades, the prevalence of asthma has been increasing hand in hand 
with industrialization, especially in the western populations (Braman, 2006). The 
increase in asthma and atopic diseases has been described as an epidemic. According 
to statistics released by American Academy of Allergy Asthma and Immunology, 
approximately 300 million people worldwide suffer from asthma and estimates 
suggesting that asthma prevalence increases globally by 50% every decade, with 
250,000 annual deaths attributed to the disease. The prevalence of asthma is 
particularly high in developed countries with highest prevalence in the United 
Kingdom (> 15%) and New Zealand (15.1%), followed by Australia (14.7%), the 
Republic of Ireland (14.6%), Canada (14.1%), and the United States (10.9% ) (Masoli 
et al., 2004). In developing countries, asthma prevalence is also increasing sharply 
with urbanization. The increase in China and India will lead to a dramatic increase in 
the economic burden due to the great populations in these two countries (Masoli et al., 
2004). The global economic costs for asthma patient care exceed those of tuberculosis 
and AIDS combined and comprise 1-2% of total healthcare budget in developed 
countries (Burr et al., 1999).  




1.1.2 Clinical symptoms of asthma and pathology 
 
People with asthma experience symptoms such as coughing, wheezing, shortness of 
breath and sometimes chest tightness when exposed to allergen in the case of allergic 
asthma. These symptoms are highly related to the ongoing inflammation particularly 
eosinophilia in the airways (Tillie-Leblond et al., 2009). In chronic asthma patients, 
there are structural changes in the airways including subepithelial and airway wall 
fibrosis, goblet cell hyperplasia, smooth muscle thickening and increased vascularity 
(Bousquet et al., 2000a; Fish and Peters, 2000) which are termed as airway 
remodeling. Airway remodeling usually occurs when the asthma patient is repeatedly 
exposed to the allergen and chronic inflammation is induced (Zosky and Sly, 2007). 
Clinically, symptoms of coughing and wheezing are often quantified by using a 
qualitative score or a visual analogue scale. However, symptoms like chest tightness, 
sputum eosinophilia and specific exercise-related symptoms are not consistently 
analyzed (Bacci et al., 2006; Green et al., 2002a). As symptoms of coughing and 
wheezing are not unique to allergic asthma, patients are usually interviewed about the 
incidence of symptoms, their day/night time occurrence and history of allergy to 
facilitate the diagnosis of asthma. 




1.1.3 Animal models of asthma 
 
Although the most relevant research on a disease are those based on patient samples 
and clinical trials in humans, owing to ethical reasons, mechanistic studies which are 
required in the search of crucial pathways and drug targets are rather limited. Thus, to 
understand the underlying mechanisms in asthma pathogenesis, to identify novel drug 
targets and develop vaccines, good animal models are essential. As no laboratory 
animals are known to develop asthma-like diseases spontaneously (Szelenyi, 2000), 
artificial models of asthma have been developed with procedures including a 
sensitization phase and followed by a challenge phase with an antigen.  
 
Various animals have been used in asthma research, including mice, rats, guinea pigs, 
dogs and sheep. Mouse models are most commonly used in the investigation on 
asthma because of the availability of various transgenic animals, the wide array of 
reagents available for analysis, the low cost in maintenance and the relatively easy 
sensitization to various antigens (Fattouh et al., 2005; Nials and Uddin, 2008). Rats 
are also popular as asthma models for they are also relatively cheap and easily 
sensitized to various antigens. Although rats were more popular than mice historically, 
mice have taken over recently due to the rapid advancement in genetic technologies 
associated with mice (Zosky and Sly, 2007). Guinea pigs are also used by some 
researchers although less commonly due to the low number of inbred strains and lack 
of specific reagents (Karol, 1994). More rarely, dogs and sheep have been used to 
develop asthma models as they have a natural pre-disposition to develop allergic 




responses (Abraham et al., 1983; deWeck et al., 1997). However, the application of 
models using dogs and sheep is rather limited because they are labor intensive and 
expensive. In this section, we will focus on the most common mouse asthma models. 
 
As asthma is a chronic disease caused by multiple factors and with different phases, 
namely the acute inflammation, chronic inflammation and airway remodeling, it is 
unlikely that a single animal mode could replicate all the features and symptoms of 
asthma. Thus, various murine models have been developed to investigate different 
stages and target different features of the disease.  
 
Acute asthma models usually comprise of 2 different phases: sensitization/booster 
and challenge. The efficiency of the models can be influenced by various factors such 
as mouse strain, choice of allergen and choice of sensitization and challenge protocol 
(Nials and Uddin, 2008). A lot of research groups use BALB/c mice for they are more 
Th2-biased and more prone to asthma (Boyce and Austen, 2005). However, other 
strains of mice are also widely used such as C57BL/6 mice (Kumar et al., 2008). 
Adjuvant is always used when ovalbumin (OVA) – a chicken egg-derived antigen is 
used as model allergen. Sensitization and booster are normally given intraperitoneally 
(i.p) while challenge with allergen is performed locally in the airways. In the case of 
natural allergen such as house dust mite (HDM), adjuvant can be spared as the 
allergen itself can induce strong immune responses in the mice even when introduced 
only locally (Hammad et al., 2009). The efficiency of immunization and challenge 
can be assessed by lots of parameters: eosinophil infiltration into the lungs and 




alveolar spaces; mucus production by goblet cells lining the epithelium of the airways; 
type II cytokine production in the airways including interleukin (IL) 4, IL-5, IL-13 etc; 
airway hyper-responsiveness  (AHR) to methacholine; IgE production in the serum if 
sensitized systemically (Holt et al., 1999; Kim et al., 2010).  
 
Acute models of asthma have the limitation that airway inflammation and AHR might 
resolve in a few weeks (McMillan and Lloyd, 2004) and that the pattern and 
distribution of pulmonary inflammation is different from human asthma (Foster et al., 
2002). Despite these shortcomings, acute asthma models are useful tools for the 
investigation of inflammatory processes in asthma and the identification of cell 
mediators. Meanwhile, to overcome the disadvantages of the acute models, 
researchers have also developed chronic asthma models with the hope of replicating 
more features of human asthma including airway remodeling and persistent AHR. 
Chronic asthma models usually involve repeated exposure to low doses of allergen 
for a long period of time up to 12 weeks and different allergens have been employed 
to develop the model including OVA, HDM, grass pollen etc (Johnson et al., 2004; 
Kim et al., 2006; Wegmann, 2008). Notably, repeated exposure to allergens especially 
OVA has a potential disadvantage that it may induce tolerance (Kumar et al., 2008). 
However, by controlling the concentrations of aerosolized OVA, tolerance can be 
minimized (Kumar et al., 2008). Using chronic asthma models, hallmarks of asthma 
such as eosinophilic inflammation, goblet cell hyperplasia and AHR are successfully 
reproduced. Some of the models also show evidence of airway remodeling, epithelial 
hypertrophy, and either subepithelial or peribronchiolar fibrosis which are featured of 




chronic inflammation. Unlike acute asthma models, some of the key features 
established in chronic asthma models have been shown to persist after the final 
challenge (Johnson et al., 2004; McMillan and Lloyd, 2004).  
 
With all different models available, research labs often adopt the one that most fits 
their purpose. Acute asthma models are usually adopted when the focus of the study 
is on inflammatory process and the mechanistic pathways involved while chronic 
asthma models are chosen when airway remodeling is of interest.  




1.2 The immune system and asthma  
 
Our immune system protects us from all kinds of infections but is also responsible for 
the development of asthma when the balance is broken. The immune system consists 
of different layers of defense with increasing specificity, from the non-specific 
physical barriers to the innate immune system and finally to the highly specific 
adaptive immune system. Physical barriers provide the first-line defense by 
preventing the entry of viruses, bacteria and fungi through mechanical (skin), 
chemical (β-defensins secreted by skin and respiratory tract) and biological 
(commensal flora) means (Agerberth and Gudmundsson, 2006; Gorbach, 1990). If 
pathogens breach the physical barriers, the innate immune system will come into play, 
almost immediately. This system, although efficient, is not specific but rather 
responds in a generic way and the protection does not last long or generate memory 
(Medzhitov, 2007). If the innate system does not successfully stop the invasion, the 
adaptive immune system is the last line of defense to combat the infection. Adaptive 
immune responses are usually triggered more slowly than the first two. However, it is 
long-lasting and highly specific by recognizing a signature antigen and memory cells 
will be generated to protect against future invasions (Pancer and Cooper, 2006).  
 
Although effective immune defenses could combat infection, there are times when the 
immune responses are not strong enough to kill pathogens or cancer cells and there 
are also times when the immune system over responds to harmless antigens or self 




antigens which then leads to disease manifestations such as asthma and autoimmune 
disorders.  
 
Asthma occurs when the body has abnormal Th2 responses to a harmless antigen 
which leads to excessive cell infiltration and inflammation at the early phase. 
Structural changes may occur during later phases when chronic antigen exposure is 
present, causing more long-lasting symptoms. The pathogenesis of asthma involves 
all layers of immune defenses, mainly facilitated by the innate and adaptive immune 
systems. An illustration of asthma progression and major mediators is shown in 
Fig1.2.1 and Fig1.2.2. The contribution of each mediator will be discussed in 
following sections.  
 























Figure 1.2.1 Illustration of events occurring at the peripheral site (lung) during 
asthma development.  
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1.2.1 Innate immune responses in asthma 
 
Innate immunity is the second-line of defense of the body which responds relatively 
quickly in a non-specific manner. Phylogenetically, this defense mechanism is 
encoded in genomic DNA (Sly and Holt, 2011). The innate immune system consists 
of a powerful sensing mechanism through pattern recognition receptors (PRR) which 
respond to microbial components and induce inflammation. PRRs include Toll-like 
receptors (TLRs) – TLR1 to TLR9, nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLRs) and retinoic acid inducible gene-I (RIG-I)-like 
receptors (RLRs) (Sly and Holt, 2011). In asthma, allergens themselves usually do not 
induce strong responses, but rather require the co-stimulation of TLRs, especially 
TLR4 (Eisenbarth et al., 2002a).  
 
The innate immune responses involve various cell types: macrophages, mast cells, 
granulocytes like basophils, eosinophils and neutrophils, epithelial cells, dendritic 
cells (DCs) and nature killer (NK) cells, of which DCs form a link between the innate 
and adaptive immunity. DCs are located within and below the airway epithelium, 
forming an extensive network and capturing antigens via the dendrites protruding 
between epithelial cells (Rate et al., 2009).  
 
1.2.1.1 Macrophages in asthma 
 
Macrophages, the major type of immune cells in the alveolar space at resting state, 
are derived from circulating monocytes which migrate to the lung under the attraction 




of the chemoattractant chemokine C-C motif ligand 2 (CCL2) or monocyte 
chemotactic protein 1  (MCP1) and CXC chemokine ligand 1 (CXCL1) (Barnes, 
2004). Macrophages are phagocytes that take up invading pathogens such as bacteria 
through phagocytosis and thus clear low-degree infections without causing obvious 
symptoms. However, their phagocytic function is not the main focus in the study of 
asthma. Macrophages were first reported to be negative mediators of asthma for they 
can negatively regulate antigen presentation by dendritic cells (DCs), T cell activation 
and immunoglobulin production (Holt et al., 1993). Moreover, alternatively activated 
macrophages (M2 cells) were shown to inhibit type II cytokine production by CD4 T 
cells (Nair et al., 2009). Despite this evidence, the role of macrophages in asthma in 
vivo remains controversial as they can produce both pro- and anti-inflammatory 
mediators, including type I, type II cytokines, IL-17 and IL-33 under different stimuli 
(Gordon, 2003). Previous studies have shown that depletion of alveolar macrophages 
resulted in reduced IL-33-induced inflammation (Kurowska-Stolarska et al., 2009). In 
addition, depletion of pulmonary macrophages could attenuate prolonged AHR while 
the depletion of either CD4 T cells or eosinophils did not (Yang et al., 2010). These 
findings suggest that macrophages could also play a role in the exacerbation of 
allergic responses apart from the negative regulatory role described earlier. It is thus 
debatable whether macrophages are beneficial or detrimental in the pathogenesis of 
asthma and researchers are still actively looking into the underlying mechanisms. 
 
 




1.2.1.2 Mast cells in asthma 
 
Mast cells, together with basophils, eosinophils and neutrophils, are recruited to the 
airways after allergen challenge. Mast cells arise from CD34
+
 pluripotent progenitor 
cells which circulate in the blood and migrate to tissues where they mature (Prussin 
and Metcalfe, 2006). Mature mast cells express a membrane-bond high affinity IgE 
receptor FcεRI which can be cross-linked by antigen-specific IgE (Prussin and 
Metcalfe, 2006). Mast cell activation through FcεRI is central to the pathogenesis of 
allergic diseases, including anaphylaxis, allergic rhinitis, and allergic asthma. Upon 
activation by allergens, mast cells degranulate and release a range of mediators 
including preformed mediators (histamine, heparin, serine proteases, proteoglycans), 
newly-synthesized lipid mediators (leukotriene A4 LTA4, LTB4) and 
cytokines/chemokines (tumor necrosis factor α (TNF-α), IL-3, granulocyte-monocyte 
colony-stimulating factor (GM-CSF), IL-8), which can contribute to immediate 
hypersensitivity reaction with symptoms like sneezing and rhinorrhea in the upper 
respiratory tract; cough, bronchospasm, and mucous secretion in the lower respiratory 
tract  (Barrett and Austen, 2009). Some of the mediators, especially the cytokines and 
chemokines are also involved in late allergic responses characterized by edema and 
cell infiltration which play a role in the persistence of asthma (Prussin and Metcalfe, 
2006). Mast cells can enhance asthma development in some asthma model (Williams 
and Galli, 2000) and mast cell-deficient mice develop less airway inflammation, 
mucus production and AHR (Taube et al., 2004).  Although mast cells can also 




function as APCs (Frandji et al., 1993), this aspect of their function is much less 
commonly investigated when compared to professional APCs such as DCs.  
 
1.2.1.3 Eosinophils and neutrophils in asthma 
 
Like mast cells, eosinophils also develop from CD34
+
 pluripotent progenitor cells in 
the presence of IL-3, IL-5 and GM-CSF while IL-5 is specific for the lineage 
commitment to eosinophils. IL-5 is also important in the release of eosinophils while 
CCL11 (eotaxin) acts as a chemoattractant for eosinophils through chemokine C-C 
motif receptor 3 (CCR3) (Rosenberg et al., 2007). IL-4 and IL-13 play an important 
role in the upregulation of CCL11, thus promote the trafficking of eosinophils to site 
of inflammation (Prussin and Metcalfe, 2006). Eosinophils express an array of cell-
surface molecules, including immunoglobulin receptors for IgG (FcγRII/CD32) and 
IgA (FcαRI/CD89) which are target receptors during activation. Eosinophils store a 
broad range of pro-inflammatory mediators including major basic proteins (MBPs), 
newly synthesized eicosanoids (LTC4), and cytokines and chemokines (TGF-β, IL-4, 
IL-5, IL-13, TNF-α, CCL11 etc) (Hogan et al., 2008). Eosinophils are recruited to the 
airways in an allergic response and eosinophilia is considered as a hallmark of asthma. 
After migration to tissue and activation, eosinophils release pro-inflammatory 
mediators to the microenvironment (Akuthota et al., 2008). Eosinophils are required 
for AHR in some asthma models, probably due to the IL-13 they produce and the 
MBPs they release (Lee et al., 2004; Pranabashis, 2011). Although MBPs are 
important in the combat against parasites, they are also contributors in inducing AHR 




in allergic patients (Prussin and Metcalfe, 2006). Moreover, eosinophils can also 
upregulate their major histocompatibility complex (MHC) class II and co-stimulatory 
molecule expression after GM-CSF stimulation which implies that they may have 
APC function as well (Lucey et al., 1989). It has also been shown that antigen-loaded 
eosinophils could promote type II cytokine production by T cells (MacKenzie et al., 
2001). However, this aspect of eosinophil function has not been extensively studied 
and remains controversial.  
 
After the failure of treating asthma by inhibiting eosinophilia using anti-IL-5 and 
corticosteroids, neutrophils came into the picture of asthma pathogenesis (Green et al., 
2002b; Leckie et al., 2000). Neutrophils are more commonly found in severe asthma 
with irreversible lung function impairment (Bousquet et al., 2000b). Activated 
neutrophils can release a large array of inflammatory mediators including 
myeloperoxidase, bactericidal/permeability increasing protein (BPI) and defensins. 
These mediators may play a role in airway inflammation and remodeling found in 
severe asthma (Bousquet et al., 2000b). 
 
1.2.1.4 Basophils in asthma 
 
Although basophils circulate in blood which distinguishes them from the tissue-based 
mast cells, these two types of cells share many common features including the 
expression of FcεRI, type II cytokine production and release of histamine after 
activation. Basophils, like mast cells and eosinophils, also develop from CD34
+
 




pluripotent progenitor cells in the presence of IL-3 (Prussin and Metcalfe, 2006).  
Aggregation of FcεRI bound by multivalent antigens activates basophils for 
exocytosis and mediator release. IL-3, IL-5, GM-CSF and histamine-releasing factor 
prime basophils and lead to enhanced degranulation and secretion of IL-4 and IL-13 
after activation (Prussin and Metcalfe, 2006). IL-33, a member of the IL-1 
superfamily, can also activate basophils, inducing them to produce IL-4 and IL-13 
and potentiate degranulation (Pecaric-Petkovic et al., 2009). The release of histamine 
and IL-4 by activated basophils can enhance immediate hypersensitivity responses 
(Kim et al., 2010).  
 
Like mast cells and eosinophils, basophils are believed to be functional APCs through 
the expression of MHC class II and co-stimulatory molecules which enable them to 
induce T cell responses. There is more evidence showing that basophils can function 
as APCs than mast cells and eosinophils. An in vitro study demonstrated that co-
culture of naïve T cells with bone marrow-derived basophils in the presence of OVA 
peptide resulted in Th2 differentiation (Sokol et al., 2009a). Another adoptive transfer 
study showed that the introduction of basophils into wild type or Ciita
−/−
 mice (which 
do not express MHC class II) followed by antigen challenges induces comparable 
levels of IL-4 production from CD4 T cells and that depletion of basophils led to 
reduced IL-4 production (Perrigoue et al., 2009; Yoshimoto et al., 2009). Moreover, 
basophils but not DCs were shown to be necessary and sufficient for the induction of 
Th2 responses in a basophil depletion study (Sokol et al., 2009a). However, it was 
later argued that the depletion did not only eliminate basophils but also a subset of 




DCs, rendering the conclusion ambiguous (Hammad et al., 2010). Nevertheless, 
basophils are important sources of IL-4 which is the crucial Th2 differentiation 
cytokine, making them important mediators in allergic diseases, regardless of their 
APC function. 
 
1.2.1.5 Epithelial cells in asthma  
 
When foreign substances enter the airway, epithelial cells are the first line of defense 
and they are increasingly appreciated as one of the key players in the pathogenesis of 
asthma (Prefontaine and Hamid, 2007). Although asthma is a Th2-mediated 
inflammatory disorder, the epithelium also plays a vital role in orchestrating the 
inflammatory responses in various ways (Wark et al., 2005).  
 
Epithelial cells and DCs  
When the epithelial integrity, more specifically, the epithelial tight junction is 
disrupted, inhaled substances can more easily pass through the airway wall and DCs 
will capture them and present them to T cells (Wang et al., 2008).  The fact that DCs 
are in vicinity of epithelial cells also supports the hypothesis that epithelial cells play 
an important role in affecting DC function. Epithelial cells produce chemokines to 
induce DC recruitment and cytokines to mediate DC activation (Pichavant et al., 2005; 
Stumbles et al., 2001). A lot of important cytokines are produced by epithelial cells 
which play crucial roles in establishing a Th2 immune response, including thymic 
stromal lymphopoietin (TSLP), GM-CSF, IL-1β, IL-33, IL-25 etc (Hammad and 




Lambrecht, 2008). TSLP binds to the receptor complex on DCs composed of IL-7 
receptor and TSLP receptor which in turn triggers the upregulation of the co-
stimulatory molecule OX-40L on DCs (Ito et al., 2005; Liu et al., 2007). This 
interaction is important for DC Th2 priming capability (Liu et al., 2007). The 
polarization of Th2 cells by TSLP-matured DCs can be further enhanced by IL-25, 
which is also produced by epithelial cells, although other cells like basophils and 
eosinophils are also producers of IL-25 (Wang et al., 2007).  The role of TSLP in the 
establishment of Th2 responses was verified and confirmed using over expression and 
knock out models. While mice with TSLP over expression have a vigorous Th2 
response in the lung, tslpr
-/-
 mice fail to develop an antigen-specific Th2 
inflammatory responses in the airways (Al-Shami et al., 2005; Zhou et al., 2005). 
Other cytokines produced by epithelial cells are also involved in Th2 responses, either 
inductive (GM-CSF) or exacerbating (IL-1β) (Stampfli et al., 1998).  
 
Epithelial cells and asthma symptoms  
Other than affecting DC functions to modulate asthma, epithelial cells are involved in 
asthma pathogenesis in many other ways. Epithelial cells have a major role in 
maintaining the homeostasis of the airway and lung microenvironment through 
various biological functions such as anti-oxidative activity, exocrine/endocrine 
secretion, mucus production and antigen presentation (Kato and Schleimer, 2007). 
Airway inflammation is largely associated with epithelial cell functions as they are 
potent producers of cytokines which favor Th2 responses directly or through the 
modification of DCs (Cookson, 2004). Epithelial cells are also important players in 




mucus hyper secretion. As downstream targets of molecules that activate the IL-13 
receptor and epidermal growth factor receptor (EGFR), epithelial cells are closely 
associated with mucus production in both protective immune responses and allergic 
airway diseases (Nadel, 2007). EGFR expression and activation can induce goblet 
cell hyperplasia and increase mucin production. Moreover, IL-4 is shown to affect 
epithelial cell IL-8 production and mucin expression (Kato and Schleimer, 2007). 
Considering the effect of epithelial cells on mucus production, together with their 
anti-oxidative activity, their role in maintaining an intact lining of the airways, it is 
not difficult to imagine that disruption of epithelial cell functions might be the first 
step towards the onset of AHR (Qin et al., 2007) (Nadel, 2007).  
 
Not only are the acute symptoms of asthma modulated by epithelial cells, chronic 
manifestations of asthma such as airway remodeling and chronic inflammation are 
also related to epithelial cells. Airway remodeling is a major contributing factor to the 
development of airflow obstruction and the decline in lung function in chronic asthma. 
(Holgate et al., 2004). The disrupted epithelial layer leads to the production of growth 
factors which interact with the underlying mesenchyme and thus promote airway 
remodeling and a more persistent inflammatory phenotype (Holgate et al., 2004; 
Prefontaine and Hamid, 2007). The impaired capacity of epithelial cell antioxidant 
activity and protective cytokine production may also render the airway more 
susceptible to hazardous environmental substances (Holgate, 2007). 
  




1.2.2 DCs in asthma – bridging innate and adaptive immunity 
 
First named by Ralph Steinmann in the 1970s for  their unique morphology, i.e. the 
long dendrite extensions, which is distinct from other mononuclear phagocytes 
(Steinman and Cohn, 1973), DCs are specialized antigen presenting cells (APCs) of 
the innate immune system which are the only APCs capable of initiating adaptive 
immune responses by priming naive T cells (Steinman, 1991). Naive T cell priming is 
a unique feature of DCs which distinguishes them from other APCs such as B-cells 
and macrophages, probably due to the high levels of MHC class I and II as well as co-
stimulatory molecule expression and long dendritic processes facilitating cell 
interaction (Raue et al., 2004).  
 
Development, differentiation and maturation of DCs  
Bone marrow progenitor cells undergo two major transformations to become DCs: 
differentiation and maturation (Fogg et al., 2006; Onai et al., 2007). The 
differentiation of the progenitor cells into DCs in peripheral tissues is critically 
dependent on receptor tyrokinase kinase Flt3 (Waskow et al., 2008) and the key 
transcription factor expressions (Merad and Manz, 2009). Newly differentiated DCs 
are usually termed as immature DCs which are functionally superior in the uptake and 
processing of foreign antigens. Upon the encounter with foreign antigens, immature 
DCs are stimulated to become mature DCs which highly upregulate surface 
expressions of MHC Class I and II as well as co-stimulatory molecules CD40, CD80 
and CD86. These mature DCs downregulate their antigen uptake capacity and 




become more efficient in antigen presentation than the immature DCs, preparing them 
for effective priming of T cells (Banchereau et al., 2000). Meanwhile, chemokine 
receptor CCR7 for homing to lymphoid tissues is also upregulated by these mature 
DCs, facilitating the migration of DCs to the site of naive T cells for priming (Gunn et 
al., 1999).  
 
Subsets of DCs  
There are various types of DCs which can be broadly categorized into lymphoid and 
non-lymphoid subsets. In peripheral lymphoid organs such as the spleen and lymph 












 DCs (Vremec et al., 2000). Each subset of DCs is specialized in unique 
functions due to differences in the expression of molecules involved in the antigen 
processing machinery (Dudziak et al., 2007) and the way that antigen is processed in 
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DCs  are highly efficient in CD4 T cell priming. In non-lymphoid tissues, the 
classification of DC subsets varies in different tissue. Two major subsets are currently 








 DCs (Edelson et al., 2010; 
Sung et al., 2006b). A small number of plasmacytoid DC are also present in the lung 






 cells, however they only 
constitute a minority population at steady state (GeurtsvanKessel and Lambrecht, 
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 monocytes (Jakubzick et al., 2008). However, 
other groups argue that lung DCs do not derive from blood monocytes at all, but 
instead originate from pre-DCs, a rare DC progenitor cell population in the blood and 





 DCs (Ginhoux et al., 2009). Similar to the distinct functions of lymphoid 









 DCs that cross-present antigens via MHC I are more efficient in the 
interaction with CD8 T cells (del Rio et al., 2007; Sung et al., 2006a). Both subsets of 
DCs are capable of producing IL-12p70 (D'Andrea et al., 1992; Sung et al., 2006a) 
which favors Th1 differentiation (Hsieh et al., 1993; Manetti et al., 1993).   
 
DC functions in asthma  
Lung DCs play an important role in the induction of tolerance to harmless inhaled 
antigens (de Heer et al., 2004; Hurst et al., 2001; Van Hove et al., 2007). One possible 
reason is that those antigens fail to fully activate the DCs for the induction of T cell 
responses (Sousa, 2006; Sporri and Sousa, 2005). Moreover, immature or partially 
mature DCs can lead to the induction of IL-10/transforming growth factor-β (TGF-β)-
producing regulatory T cells in an IL-10 and inducible T cell co-stimulator ligand 
(ICOSL)-dependent manner (Akbari et al., 2001; Akbari et al., 2002). However, the 
presence of extra signals can break the tolerance. DCs express lots of PRRs, including 




TLRs, NLRs and RLRs.  Stimulation of TLR4 with low dose of lipopolysaccharide 
(LPS) is efficient to break the tolerance and induce allergic responses to OVA 
(Eisenbarth et al., 2002c). The number of CD11b
+
 DCs increased largely in the 
conducting airways and lung interstium of sensitized and challenged mice, suggesting 
the potential role of DCs in asthma (Beaty et al., 2007). Both DC depletion and 
adoptive transfer studies further show that DCs play a crucial role in the development 
of asthma (Lambrecht et al., 2000; van Rijt et al., 2005). It was also recently 
suggested that basophils and not lung DCs are necessary and sufficient for the 
induction of Th2 immunity to inhaled antigen (Sokol et al., 2009b). However it was 
later shown that the use of anti-FcεRI to deplete basophils also resulted in a 
concomitant depletion of a subset of inflammatory DCs which also expressed FcεRI, 
thus making the conclusion on the role of basophils invalid (Hammad et al., 2010). As 
discussed earlier, functions of DCs are highly dependent on epithelial cells.  
Epithelial cells release various chemokines and cytokines such as GM-CSF, TSLP, 
IL-25 and IL-33, which could skew DC function towards a Th2 activating mode 
(Lambrecht and Hammad, 2010).  




1.2.3 Adaptive immune responses in asthma  
 
The adaptive or specific immune system which mainly involves the lymphocytes is 
activated by the non-specific immune system and comes into play at a later phase. It 
has the ability to recognize specific pathogens as the lymphocytes have a vast number 
of different antigen receptors uniquely expressed on their surface. Responses of this 
system result in memory cell generation and thus confer long-lasting protection 
against future invasions. Although adaptive immunity is the key to clear viral 
infections and combat other diseases, it is also responsible for asthma development.    
 
The adaptive immune responses involved in asthma include the two arms of the 
system: Humoral and cell-mediated responses. B cells or rather plasma cells that they 
differentiate into are the major components of the humoral immune responses, while 
cell-mediated immune responses involve both CD4 T cells and CD8 T cells. Both 
CD4 and CD8 T cells have a few different subsets which play different roles in the 
pathogenesis of asthma.  
 
1.2.3.1 Humoral immune responses in asthma 
 
Humoral immune responses are mediated by secreted antibodies produced by plasma 
cells, which differentiate from B cells. B cells originate from the bone marrow where 
they develop from the multipotent hematopoietic stem cells until the immature stage 
with IgM expression on the surface. These immature B cells continue to develop and 
become mature B cells with the expression of both IgD and IgM which then enter the 




blood and migrate to the lymphoid organs, mainly the spleen (Vale and Schroeder, 
2010). At this stage, the B cells are still naïve without antigen encounter. With the 
help of APCs such as follicular DCs (FDCs) and T helper cells (which will be 
discussed in the following section), antigen can be introduced to B cells and they will 
undergo affinity maturation and isotype switching (Vale and Schroeder, 2010).   
 
In asthma, plasma cells are heavily biased towards the production of IgE (Gould and 
Sutton, 2008). IgE is an important mediator in asthma pathogenesis and has been 
recognized as one of the hallmarks of asthma. It binds to its effector cells (mast cells 
and basophils) through the high affinity receptor FcεRI and primes them for the 
response to an antigen (Fahy, 2006). After antigen encounter, cross linking of the 
receptors on mast cells and basophils leads to degranulation and the release of various 
mediators in the early phase of allergic responses. The cytokines and chemokines 
liberated in this early phase are also responsible for the initiation of the late phase of 
allergic responses (Gould and Sutton, 2008). Although mast cells and basophils are 
the most well known effector cells for IgE, some structural cells in the airway, such as 
epithelial cells and smooth muscle cells also express receptors for IgE (Fahy, 2006) 
and may participate in the development of asthma.  
 
1.2.3.2 Cell-mediated immune responses 
 
As opposed to humoral immune responses which depend on antibodies, cell-mediated 
immune responses center around T cells including CD4 (the helper) and CD8 (the 




cytotoxic) T cells along with the cytokines they produce. CD4 T cells play a major 
role in the pathogenesis of asthma while the involvement of CD8 T cells has also 
been recognized although not as significantly as CD4 T cells (Lloyd and Hessel, 
2010). Both CD4 and CD8 T cells exist in different subsets with unique features and 
play distinctive roles in asthma.  
 
1.2.3.2.1 CD4 T cells in asthma  
 
CD4 T cells are recognized as helper T cells as opposed to cytotoxic CD8 T cells. 
CD4 T cells are not directly involved in phagocytic or cytotoxic activities, but rather 
serve as helpers for other cells such as B cells (for affinity maturation and isotype 
switching), CD8 T cells and macrophages, either through cell-cell interaction or 
through the cytokines they produce. CD4 T cells, as the predominant lymphocyte 
population that infiltrate the airway in asthma, are believed to play a central role in 
the inflammatory processes (Corrigan et al., 1988; Walker et al., 1992). Starting from 
the basic T helper 1 (Th1) and T helper 2 (Th2) subsets, more and more subsets of 
CD4 T cells have been identified including Th17, Th9 and regulatory T cells, 
according to the cytokine production profile and the transcription factors that govern 
their differentiation (Lloyd and Hessel, 2010). All these subsets are involved in 
asthma development in one way or another, some responsible for the manifestation of 
the disease and others inhibiting disease onset or progression.  
 
 




Th2 cells in asthma  
CD4 T cells differentiate into Th2 lineage under the control of the transcription factor 
Trans-acting T-cell-specific transcription factor 3 (GATA-3) (Ouyang et al., 1998; 
Zhang et al., 1997a). Th2 cells are characterized by the cytokines they produce 
including IL-4, IL-5, IL-10 and IL-13. The number of Th2 cells in the airways of 
asthma patients is largely increased which categorized asthma as a Th2-mediated 
disease (Bentley et al., 1992; Robinson et al., 1992). Studies have shown that Th2 
cells and together with the cytokines that they produce play a central role in the 
initiation and maintenance of the key features of asthma such as IgE production, 
airway inflammation and AHR (Cohn et al., 2004). Notably, the number of Th2 cells 
in the airway positively correlates with the severity of asthma in both humans and 
mouse models (Larché et al., 2003). 
  
Different cytokines are responsible for different aspects of disease manifestation. IL-4, 
for example, is important in Th2 differentiation and B cell isotype switching to IgE 
production (Finkelman et al., 2010b). Thus, IL-4 is more involved in the priming 
phase of allergic responses. Indeed, IL-4-deficient mice failed to develop allergic 
inflammatory responses due to defective Th2 priming (Brusselle et al., 1994) while 
blockage of IL-4 during the challenge phase did not affect the establishment of 
inflammation (Coyle et al., 1995b), further proving that IL-4 is required at the 
priming phase and once Th2 priming has occurred, IL-4 is no longer necessary. IL-5 
and IL-13 on the other hand, are involved mainly at the elicitation phase of allergic 
responses. More specifically, IL-5 is crucial for the survival and migration of 




eosinophils while IL-13 plays a more complicated role. Other than the so called 
redundant role that IL-13 plays in the isotype switch of B cells, IL-13 is also 
important in the development of AHR, mucus secretion and airway remodeling 
(Finkelman et al., 2010a). 
 
Th1 cells in asthma 
The differentiation of Th1 cells is governed by the T box transcription factor T-bet 
and IL-12 (Athie-Morales et al., 2004; Szabo et al., 2000). Th1 cells are characterized 
by the dominant production of the typical type I cytokine interferon gamma (IFN-γ) 
(Szabo et al., 2000). Th1 responses are more thoroughly investigated in infectious 
diseases such as influenza infection than in allergic diseases. As both Th1 and Th2 
cells have the ability to suppress the differentiation and activation of each other 
(Abbas et al., 1996), although Th1 cells are not directly involved in asthma, they may 
regulate asthma through their inhibitory effect on Th2 cells. It could be inferred that a 
relative deficiency in Th1 immunity might lead to enhanced Th2 immunity hence 
exacerbated allergic responses and vice versa. Indeed, the hygiene hypothesis 
proposed that reduced exposure to Th1-inducing infections such as mycobacteria or 
viruses could lead to uncontrolled Th2 responses and increased incidence of allergic 
diseases (Shirakawa et al., 1997; von Hertzen et al., 1999). However, although 
adoptive transfer of antigen-specific Th1 cells reduced the number of eosinophils in 
the bronchoalveolar lavage (BAL) fluid, they failed to counterbalance the airway 
hyperreactivity induced by Th2 cells and histological examination showed even 
higher inflammatory index in the lung tissue (Hansen et al., 1999b). Other studies 




with a similar adoptive transfer approach also showed that Th1 cell transfer did not 
successfully alleviate Th2 inflammation, but rather enhanced eosinophilia (Li et al., 
1998; Randolph et al., 1999a). Thus, the role of Th1 cells in the pathogenesis of 
asthma is still controversial and less therapeutically promising. The role of IFN-γ in 
asthma is not clearly defined either. Although evidence showed that an increase in 
IFN-γ either due to the enhancement in Th1 response or the lack of IL-4/Th2 could 
limit inflammatory responses by preventing egression of eosinophils, it could not 
prevent Th2-mediated inflammation altogether (Cohn et al., 2001). Similarly, IFN-γ 
artificially introduced via inhalation did not yield a satisfactory result but indeed 
induced more infiltration of lymphocytes in the airways (Boguniewicz et al., 1995).  
 
Th17 cells in asthma  
Th17 cells represent a recently described subset of CD4 T cells characterized by the 
transcription factor retinoid acid receptor-related orphan receptor-gamma t (RORγt) 
and the production of IL-17 (Harrington et al., 2005; Park et al., 2005). While Th1 
differentiation is directed by IL-12 and Th2 differentiation is directed by IL-4 (and/or 
IL-13), Th17 differentiation is directed by transforming growth factor β (TGF-β) and 
IL-6 with IL-23 crucial for the regulation of Th17 cells in mice (Al-Ramli et al., 2009; 
Mangan et al., 2006). However, it is still not clear which cytokines are involved in 
human Th17 development (Alcorn et al., 2010). IL-17 has various isoforms such as 
IL-17A and IL-17F. IL-17A particularly, has been found to be upregulated in the 
lungs of asthmatic patients and the level of which correlates with the severity of 




asthma, especially in patients with neutrophilic and steroid-resistant asthma (Al-





have been found in patients with asthma (Pene et al., 2008). Studies have shown that 
Th17 cells are more responsible for the infiltration of neutrophils and also involved in 
acute AHR (He et al., 2007; Wilson et al., 2009).  Models of IL-23 neutralization, IL-
23 overexpression and antigen-specific Th17 cell transfer showed that Th17 cells 
could exacerbate Th2 cell-mediated airway eosinophilic inflammation (Wakashin et 
al., 2008). Moreover, a study with adoptive transfer of Th17 cells also showed that 
Th17 cells promoted steroid-resistant airway inflammation and AHR (McKinley et al., 
2008). Thus, Th17 cells and the cytokines they produce are closely related to asthma 
pathogenesis and particularly relevant in severe and steroid-resistant asthma.  
 
Regulatory T cells in asthma 
As discussed earlier, the lung provides a suppressive environment for non pathogenic 
and harmless substances. Studies have shown that harmless antigens entering the lung 
usually induce tolerance or minimal Th2 responses and regulatory T cells (Treg) cells 
represent a major cell type that is responsible for peripheral tolerance (Hawrylowicz 




 T cells 
which express the transcription factor forkhead box 3 (Foxp3) and produce IL-10 and 
TGF-β (Ray et al., 2010). Tregs cells are commonly known for their suppressive 
effect on the proliferation and functioning of effector T cells and thus regulating 
disease progression (Lloyd and Hawrylowicz, 2009; Ray et al., 2010). The adoptive 
transfer of Treg cells was shown to suppress allergic inflammation and AHR via IL-




10-dependent mechanisms (Kearley et al., 2005). Even when transferred after the 
onset of the disease, Treg cells were still able to attenuate established inflammation 
and suppress airway remodeling (Kearley et al., 2008). The suppressive role of Treg 
cells have been extensively demonstrated in depletion studies. Depletion of Treg cells 
before sensitization enhanced the degree of inflammation and AHR (Lewkowich et al., 
2005). Depletion of Tregs also resulted in increased numbers of airway DCs with 
higher activation marker expressions and enhanced effector cell proliferation 
(Lewkowich et al., 2005).  
 
1.2.3.2.2 CD8 T cells in asthma 
 
While CD4 T cells which consist of many subsets play complicated roles in asthma, 
the participation of CD8 T cells in asthma is equally sophisticated. CD8 T cells first 
appeared in the literature as T cells with immunoregulatory functions for they could 
inhibit allergic sensitization to OVA represented by IgE (Tada et al., 1972). These 
regulatory cells were later shown to be CD8 T cells (Okumura et al., 1977) and their 
inhibitory effect on IgE was further demonstrated by different groups (Diaz-Sanchez 
et al., 1993; Sedgwick and Holt, 1984). Subsequently, CD8 T cells were also shown 
to attenuate Th2 responses in the airways (Ishimitsu et al., 2001; Renz et al., 1994; 
Wells et al., 2007a). However, it became apparent that there are different subsets of 
CD8 T cells when several subsequent studies showed that in contrast to their 
suppressor activity, CD8 T cells could also contribute to allergic responses 
(Hamelmann et al., 1996; Holmes et al., 1996; Miyahara et al., 2004b).  




CD8 T cell subsets  
Following the identification of Th1 and Th2 subsets for CD4 T cells, CD8 T cells 
which were previously thought to be present only in the form of an IFN-γ-producing 
subset, were also found to exist in at least 2 subtypes: Tc1 and Tc2 (Croft et al., 1994a; 
Noble et al., 1995; Seder et al., 1992).  Although the cytokines required for the 
differentiation into Tc1 and Tc2 are similar to those for CD4 T cells: IL-12 for Tc1 
and IL-4 for Tc2 (Croft et al., 1994a; Salgame et al., 1991), there are some important 
distinctions. The fact that IL-12 enhances Tc1 but not Tc2 growth and CD8 T cells are 
capable of producing IFN-γ independent of IL-12 suggests that CD8 T cells might be 
biased towards the differentiation into the Tc1 phenotype (Carter and Murphy, 1999; 
Croft et al., 1994a).  Moreover, Tc2 cells, unlike Th2 cells which dominantly produce 
cytokines like IL-4, IL-5, IL-13 but not IFN-γ, retain some of their ability to produce 
IFN-γ and also produce lower level of IL-4 than Th2 cells (Croft et al., 1994b).  
 
Protective effect of CD8 T cells in asthma  
CD8 T cells play a complicated role in asthma with both suppressive and potentiating 
effects described by different groups using different approaches. Depletion of CD8 T 
cells resulted in potentiated inflammation and AHR in a rat model of asthma 
concurrently with reduced IFN-γ and IL-2 expression suggesting that the suppressive 
role of CD8 T cells mainly attributes to the Tc1 subtype which predominantly 
produces IFN-γ (Allakhverdi et al., 2000; Huang et al., 1999). Another depletion 
study has also associated the lack of CD8 T cells with enhanced airway remodeling in 
a chronic asthma model (Tsuchiya et al., 2009). On the other hand, adoptive transfer 




studies have also reached a similar conclusion. In a rat model of asthma, adoptive 
transfer of CD8 T cells resulted in the suppression of late phase allergic responses and 
the increased proportion of IFN-γ
+
 cells in the lung. Similar findings were also 
observed in mouse models of asthma (Renz et al., 1994; Suzuki et al., 1999). Studies 
specifically focusing on Tc1 cells were also carried out by a few groups and further 
proved that Tc1 cells could attenuate asthma. One of the studies showed that in mice 
over expressing IL-15 which resulted in the preferable differentiation of Tc1 cells 
exhibited reduced eosinophilia when compared to wild type mice. When the CD8 T 
cells from these IL-15 transgenic mice were transferred to wild type mice before 
sensitization, Th2 responses were suppressed further confirming that Tc1 cells are 
protective against Th2 inflammation (Ishimitsu et al., 2001). Later on, another group 
demonstrated that OVA-specific CD8 T cells, when transferred to naive mice 
followed by OVA challenge, displayed a Tc1 phenotype. When these cells were 
transferred to sensitized mice, eosinophilia was inhibited following OVA challenge 
(Wells et al., 2007b). The inhibition was shown to be dependent on IL-12 production 
implying that CD8 T cells may exert their inhibitory role by antagonizing Th2 
responses or rather promoting Th1 responses.   
 
Detrimental effect of CD8 T cells in asthma  
While Tc1 cells evidently confer protection against the pathogenesis of asthma, Tc2 
cells play a much different role. The majority of CD8 T cells found in the lungs of 
asthma patients are those of the Tc2 phenotype, with the production of type II 
cytokines IL-4, IL-5 etc (Meissner et al., 1997; Ying et al., 1997). Similar findings 




were also observed in OVA-immunized and challenged mice (Coyle et al., 1995a; 
Stock et al., 2004a). These observations suggest that in the natural course of allergic 
sensitization, Tc2 subset can be generated in the lung and may contribute to the 
exacerbation of inflammation. Indeed, studies with the adoptive transfer of Tc2 cells 
have demonstrated enhanced eosinophilia and AHR, further confirming the 
detrimental role of Tc2 cells in mouse models of asthma (Cho et al., 2005; Sawicka et 
al., 2004; Schaller et al., 2005; Stock et al., 2004a). A correlation has also been 
identified between the abundence of CD8 T cells and annual decline in FEV1 in a 
prospective study of human asthma (van Rensen et al., 2005).  CD8 T cells might 
exert their role in promoting the pathogenesis of asthma via the production of 
cytokines like IL-4, IFN-γ and IL-17 as shown in a study of allergic asthma (Zhao et 
al., 2011).  
 
Non-classic CD8 T cells in asthma  
Other than the classic αβ
+
CD8 T cells investigated in most studies concerning CD8 T 
cells, γδ
+
CD8 T cells were also shown to play a role in the regulation of allergic 
responses, although it remains controversial. While one group demonstrated that 
γδ
+
CD8 T cells were required in establishing allergic airway inflammation, other 
groups claimed that γδ
+
CD8 T cells could negatively regulate airway 
hyperresponsiveness and late allergic responses (Isogai et al., 2007; Isogai et al., 2003; 
Lahn et al., 1999; Zuany-Amorim et al., 1998). The choice of animal models and 
protocols might have contributed to the controversy. Moreover, similar to CD4 T cells, 
there are also regulatory CD8 T cells present although much less extensively studied. 














 T cells, TGF-β-producing CD8 T cells, IL-10-








 T cells (Gilliet and Liu, 
2002; Kang et al., 2005; Manavalan et al., 2004; Rifa'i et al., 2004; Xystrakis et al., 
2004). However, little is known about the role of these regulatory CD8 T cells in the 
pathogenesis of asthma due to the limited availability of tools for identification and 
purification. Recently, a new subset of CD8 T cells Tc17 was also described 
(Intlekofer et al., 2008) and IL-17 produced by these cells was shown to be pro-
inflammatory in pulmonary pathology (Yen et al., 2009). In addition, the effector and 
memory status of CD8 T cells may also be critical in influencing their regulatory 
effects with the effector phenotype exhibiting a strong bias toward promotion of 
allergic responses (Miyahara et al., 2004a; Taube et al., 2006). 
 




1.3 Aims of the study  
 
Harnessing the ability of CD8 T cells to induce immune deviation of an allergic Th2 
response represents a promising strategy for attenuating inflammation, but the role of 
CD8 T cells in allergic inflammation remains controversial. The contribution of CD8 
T cell-derived IFN-γ in Th1-polarization during pulmonary Th2 inflammation is 
similarly poorly understood. The present study sought to address the ability of CD8 T 
cells of a specific phenotype to regulate allergic responses focusing on the role of 
IFN-γ as well as pulmonary DCs in a mouse model of OVA-induced asthma. Antigen-
specific effector CD8 T cells were used in our study and introduced to immunized 
mice before allergen challenge. The participation of lung parenchyma DCs in the 
regulatory role of CD8 T cells was assessed using an ex-vivo co-culture with CD4 T 
cells. In order to better identify the role of IFN-γ in the modulating effect of CD8 T 




mice. Our results showed that 
Tc1-like antigen-specific effector CD8 T cells could attenuate eosinophil infiltration 




 DCs, from CD8 T 
cell-transferred recipient mice were capable of biasing CD4 T cells towards Th1. 
However, in the absence of IFN-γ, CD8 T cells became less cytotoxic and more 
Tc2/Tc17-like when activated, which induced an asthma-like pathology in non-
immunized mice and caused exacerbation of inflammation in immunized and 
challenged mice. 





1. Establish a robust asthma model using OVA antigen and alum as adjuvant 
2. Identify the differences between OT-I and IFN-γ
-/-
OT-I CD8 T cells in terms 
of surface molecule expression, cytokine production and cytotoxic activity. 
3. Analyze the roles of OT-I and IFN-γ
-/-
OT-I CD8 T cells on the Th2 responses 
induced by OVA.  
4. Dissect the underlying mechanisms responsible for the regulatory effect of 
CD8 T cells on asthma  




CHAPTER 2: Materials and Methods 
 
2.1 Media and buffers 
PBS buffer  
 
PBS is purchased from 1
st
 base as a 10× stock which consists of 137mM NaCl, 
2.7mM KCl and 10mM phosphate buffer. The working solution is made by diluting 




MACS buffer consists of 1× sterile PBS supplemented with 2% FCS and 5mM 




FACS buffer consists of 1 × PBS supplemented with 1% FCS and 5mM EDTA. 
0.05% sodium azide is added as a preservative to permit use and storage under non-
sterile conditions. The pH of the buffer is adjusted to 7.2-7.4.  
 
Permeabilization buffer for intracellular staining  
 
Buffer used for intracellular staining is PBS containing 0.5% BSA, 0.1% saponin and 
0.1% sodium azide, adjusted to a pH of 7.2 to 7.4. Alternatively, commercially 




available permeabilization/fixation and permeabilization/wash buffers are purchased 
from BD biosciences, Singapore.  
 
Optiprep density centrifugation media for lung DC isolation 
 
Optiprep is provided as a 60% w/v solution with a density of 1.32 g/ml. Endotoxin 
level is tested and certified to be less than 0.13EU/ml. The stock is diluted using 
Optiprep diluent (formula below) to 11.173 % w/v (5.515 × dilution with Optiprep 
diluent) with a density of 1.062 g/ml. The required density is calculated using the % 
w/v to density (g/ml) linear relationship represented by the formula:  
            y = 0.0052 x + 1.0054 Where y = density, x = % w/v. 
Optiprep diluent consists of 0.8% (w/v) NaCl , 5 mM EDTA, 10 mM Tricine            
(C6H13NO5)-NaOH, pH 7.4 and made under sterile conditions. 
Optiprep Formulation for a density of 1.064g/ml 
Vol. of OPTIPREP 
/ml 




18.62 81.38 100 
37.24 162.76 200 
55.87 244.13 300 
74.49 325.51 400 
For 
1.064g/ml 
93.11 406.89 500 
 
Liberase for tissue digestion 
 
Liberase TL Research Grade (low thermolysin concentration) is obtained from Roche 
(Roche Applied Science) and dissolved in plain RPMI-1640 to obtain a concentration 
of 2mg/ml which corresponds to a colleganse activity of 0.52 Wünsch units/ml. This 




forms a 10× Liberase stock solution which is aliquoted and stored at -30
o
C. For 
digestion of tissues, the 10 × Liberase stock solution is diluted 10-fold with plain 
RPMI-1640 and supplemented with 1% v/v FCS, which is added to preserve the 
viability of DCs. 
 
Complete medium for cell culture 
 
1. Swab surfaces as well as bottles with 70% ethanol. 
2. Add the following to 500ml RPMI-1640:               
57.5ml FCS (10%) (Gibco), heat-inactivated for 30 mins 
5.75ml Non-essential amino acids (1% v/v) (Sigma aldrich) 
5.75ml Sodium Pyruvate (1mM) (Sigma aldrich) 
5ml Streptomycin (100IU/ml) / Penicillin  (0.1mg/ml) (Sigma aldrich) 
28.75ul β-mercaptoethanol (50uM) (Sigma Aldrich) 
                                ---------------------------------------------- 
                                   574ml of Complete RPMI medium 
3. Swirl to mix. 
4. Store complete RPMI medium in 4
0
C for further use. 
 
Complete DMEM for cell culture 
 
The preparation of complete DMEM is similar to complete medium. Dulbecco’s 
Modified Eagle Medium with L-Glutamine and 4.5g/L D-glucose (Gibco) is used 
instead of RPMI-1640. 




Buffers for ELISA 
 
Wash buffer is PBS with 0.5 % v/v Tween-20, pH adjusted to 7.2 to 7.4. Block buffer 
is PBS with 1 % w/v BSA, pH adjusted to 7.2 to 7.4. 
 
RBC lysis buffer 
 
1. To make a 10× stock, add 82.9g Ammonium chloride, 10g sodium 
bicarbonate and 2ml of 0.5M EDTA into a 1L Schott bottle.  
2. Make up to 1 L by diluting and adding deionized H2O. Use magnetic stirrer to 
stir contents. Adjust pH to 7.2-7.4. 




1. Make a 4% paraformaldehyde (Sigma Aldrich, US) solution (w/v).  
Paraformaldehyde is toxic. Avoid inhaling the particulate matter when 
weighing out the powder. Weigh it in a fume hood, a mask is recommended. 
 
2. Mix the paraformaldehyde/PBS solution, which will be cloudy white. 
Incubate in the water bath at 60°C for approximately 40 mins. The 
paraformaldehyde will settle at the base of the falcon tube, and will need to be 
resuspended every 10 mins or so.  
 




3. When the solution is clear, aliquot and store at -30
o
C for long-term storage or 
4
o




Age- and sex-matched C57BL/6 mice (8-10 weeks) are purchased from the animal 
breeding centre of National University of Singapore (NUS). OT-I and OT-II mice are 
purchased from Charles River Laboratories (Wilmington, MA). OT-I CD8 T cells 
recognize ovalbumin peptide OVA257-264 (SIINFEKL) associated with H-2K
b
, while 
OT-II CD4 T cells recognize ovalbumin peptide OVA323-339. IFN-γ
-/-
 mice are 





mice, OT-I mice are cross-bred with IFN-γ
-/-
 mice for 3-5 generations. 
Mice expressing OT-I TcR (Vα2/Vβ5) transgene and are IFN-γ
-/-
 are chosen by 
genotyping for further breeding and research use. All mice are maintained under 
pathogen-free conditions in satellite animal housing unit of the centre for 
Comparative Medicine. All experiments are conducted in accordance with 
institutional guidelines and approved by NUS institutional animal care and use 
committee (IACUC) under protocol number 029/09. 
 
2.3 Asthma model: Sensitization and airway challenges 
2.3.1 Precipitation of OVA-alum 
 
1. Dissolve OVA (grade V; Sigma Aldrich, USA) at 10mg/ml in sterile PBS. 




2. Add 4.5ml of 1M NaHCO3 in sterile distilled water to 10ml of the antigen 
stock solution at room temperature and gently mix. 
3. Add 10ml of 0.2M KAl (SO4)2.12H20 in sterile distilled water (preferably 
freshly prepared) drop-wise to the mixture while stirring. Maintain the 
mixture at 25°C for 20 minutes and then centrifuge at 3000g for 10 minutes.  
4. Wash the precipitate three times in sterile PBS. 
5. After the last wash, discard supernatant and re-suspend the cell pellet in 10ml 
of sterile PBS. 
6. Store alum-antigen mixture at 4°C for up to 24 hours. 
7. Dilute the 10mg/ml alum/OVA mixture 1:10 prior to injection.  
 
2.3.2 Sensitization and challenge protocol 
 
1. At day zero, inject 100µl of 1mg/ml OVA/alum intraperitoneally (i.p.), 
resulting in 100µg per mouse. 
2. At day 14, inject another 100µg per mouse as a booster. 
3. The intranasal challenges take place at days 21, 22, 23. To challenge the mice, 
make up OVA in sterile PBS at a concentration of 5mg/ml for the intranasal 
challenge. Connect the isofluorance machine to the isolfluorane chamber 
within the BSC. Turn the machine on, open the oxygen tap and set the 
isofluorance dial to 4. After a minute, add the mice to chamber (a maximum 
of 6 at one time), and wait until they have become knocked out, with a 
shallow, steady rate of breathing.  




4. Remove the anesthetized mouse from the chamber and administer 20µl of 
OVA solution to the nares of the nostril. Place the mouse back in the chamber 
to keep it under anesthesia. Repeat with all the mice until they have received 
the inoculations. Put them back into the cage. 
5. After all the mice have been inoculated, turn off the isofluorane and oxygen 
taps. 
6. After 3 successive days of intranasal challenges the mice are ready for 




2.4 CD8 T cell isolation, activation, CFSE labeling and adoptive transfer 
2.4.1 Isolation and activation of CD8 T cells 
 
1. Obtain spleens and lymph nodes from OT-I, IFN-γ
-/-
OT-I mice or CD45.1 
C57BL/6 mice. 
2. Cut the spleens to small pieces and digest together with lymph nodes in 
1×liberase buffer for 30 mins.  
3. Pass the digested tissues through the cell strainer and obtain a single cell 
suspension. 
4. Centrifuge cell solution at 600g for 5 mins at 4
o
C. 
5. Remove supernatant and wash the cells with MACS buffer at least once and 
centrifuge the cells at 450g for 5 mins at 4
o
C. 
6. Remove supernatant and re-suspend cells in MACS buffer and perform 
density centrifugation with Ficoll-plaque plus (GE healthcare, Sweden) to 




enrich the lymphocytes. Cells need to be layered gently on top of Ficoll and 
centrifuge at 600g for 20 mins at RT with minimum acceleration and brake.  
7. Collect the cells at the interface and spin down at 600g for 5 mins at 4
 o
C. 




9. Re-suspend cells with 4µl of microbeads (Miltenyi Biotec, Singapore) / 10
7
 
total cells or as written in the instruction sheet. Mix well. 
10. Incubate in 4
 o
C fridge for 30 mins. Mix gently every five mins for the first 15 
mins of incubation and leave the cells untouched for the remaining 15 mins.  
11. Wash once with MACS buffer. 
12. Centrifuge at 450g for 5 mins at 4
 o
C. 
13. Remove supernatant and re-suspend cells in 2ml of MACS buffer. 
14. Prepare the appropriate MACS column. 
15. Prepare LS column by rinsing with 1ml of MACS buffer.   
16. Apply the cell suspension into the column.  
17. Perform washing steps by adding 3ml of MACS buffer 2-3 times. 
18. Remove column from separator and place on a new 15ml tube. 
19. Pipette 3ml of MACS buffer into column and flush out the magnetically 
labeled fraction by applying the plunger. 
20. Centrifuge cells at 450g for 5 mins at room temperature. 
21. Aspirate out the supernatant and re-suspended cells with complete RPMI. 
22. Count the purified cells. 




23. Re-suspend cells at 0.67×10
6
 in complete RPMI. Add PMA (10µg/ml) (Sigma 
Aldrich, USA) and ionomycin (400µg/ml) (Sigma Aldrich, USA) to the 
culture and incubate in a 37
 o
C incubator with 5% CO2. 
24. Monitor cell growth. Harvest cells after 48 hours. 
 
2.4.2 CFSE labeling and adoptive transfer 
 
25. Wash the harvested cells in sterile PBS twice and re-suspend them in warm 
PBS at the appropriate concentration for CFSE labeling (20×10
6
 cells per ml). 
26. Prepare CFSE (Invitrogen, USA) by diluting the stock to 10µM. 
27. Mix cells with CFSE at 1:1 ratio which achieves a final concentration of cells 
at 10×10
6
 cells/ml and concentration of CFSE at 5µM. 
28. Incubate cells at 37
 o
C in the dark for 15 mins. 
29. Stop reaction by quenching with 15ml complete RPMI. Incubate the cells on 
ice for 5 mins. 
30. Spin down cells at 450g for 5 mins and wash twice with PBS. 
31. Resuspend cells in PBS at the concentration of 15×10
6
 cells per ml.  
32. Restrain the recipient mice in mouse restrainer after lidocane application at 
the tails and sufficient heating using a lamp. Transfer 3×10
6
 cells (200µl) into 
recipient mice through intra-venous injection through the tail vein. 
 




2.5 Bronchoalveolar lavage analysis 
1. Sacrifice mouse by i.p injection of pentobarbital obtained from the pharmacy 
of animal holding unit (0.1ml/mouse) or via carbon dioxide asphyxiation. 
2. Cannulate the trachea with a needle with plastic tubing and flush the lungs 
with 2 × 0.7ml aliquots of MACS buffer. Transfer each instillation into an 
eppendorf tube. 
3. Spin down the cells at 450g for 5 mins and save the supernatant (BALF) for 
analysis of cytokine levels by ELISA. 
4. Carry out RBC lysis by suspending the cells in 0.2ml of red blood cell lysis 
solution if there appears to be red blood cells in the cell pellet. This is to be 
done at room temperature for 1 minute. Red blood cell lysis must be quenched 
by adding MACS buffer.  
5. Resuspend the cells in 1ml MACS buffer.  
6. Count the cells using a haemocytometer. The numbers will be used to 
determine total cell count. Adjust the concentration to 1 × 10
5
 cells/ml. 
7. Stain cells using antibodies: Siglec-F-PE (BD biosciences, USA), Ly-6G-APC 
(BD biosciences, USA), CD11c-PerCP/Cy5.5 (Biolegend, USA) and CD3-PB 
(Biolegend, USA) and analyse using flow cytometry or sort different cells 
using MoFlo (Beckman Coulter, USA). To differentiate live cells from dead 
cells, add 0.5µl of 7-amino-actinomycin D (7AAD) (Sigma Aldrich, USA) 
prior to flow cytometric analysis. In the case of employing 7AAD, 
PerCP/Cy5.5 and PE-cy5 channel should be avoided. 
 




To stain the sorted cells on glass slides: 
1. Resuspend sorted cells at a concentration of 1 × 10
5
 cells/ml.  
2. Load 20µl of the solution into the funnel and spin down the cells onto a slide 
using cytospin.  
3. Stain the cells using hematoxylin and eosin (Sigma Aldrich, USA). 
 
2.6 Ex vivo assay of lung parenchymal dendritic cells 
 
1. Cut the renal artery to drain most of the blood.  
2. After lavage, excise lungs from thoracic cavity. Remove the esophagus and 
trachea which may be attached to lung tissues after excision. 
3. Prepare digestion buffer (1 × Liberase in plain RPMI supplemented with 1 % 
FCS) and use 1.5 ml per lung. Scale up accordingly if more than one lung is 
being digested.  
4. In a falcon tube, cut lungs with scissors into fine pieces in liberase digestion 
buffer. It is important to cut the tissue finely as this will affect the efficiency 
of digestion. 
5. Digest for 45 mins. Resuspend vigourously with a pasteur pipette at 20 
minutes time point to aid in breaking up tissue clumps. 
6. After incubation, place digested tissue onto sterile cell strainer that is placed 
onto the 50ml tube. A maximum of 4 lungs should be placed per mesh.  




7. To obtain single cell suspension, press lungs onto the cell strainer using a 1 ml 
syringe head. Do this intermittently with the addition of MACS buffer onto 
the cell strainer to release cells into the falcon tube. 
8. Spin down the single cell suspension and wash the cell pellet. 
9. Repeat washing, centrifuge at 450g for 5 mins at 4
o
C.  
10. Obtain a dry cell pellet by discarding as much of the supernatant as possible. 
To the cell pellet, add 3 ml of Optiprep solution (g = 1.064).  Spilt into several 
tubes if using more than 4 lungs. Disrupt cell pellet and avoid cell clumping 
by pipetting several times. Transfer cell solution to 15 ml falcon tube.  
11. Layer 2 to 3 ml of FCS onto the optiprep cell solution.  
12. Spin cells at 1700g for 10 mins at 4
o
C. Brakes and acceleration should be set 
to minimum (set to 0). 
13. Harvest cells accumulating at the interface by transferring the cells to a new 
15 ml falcon tube. Top up tube with MACS buffer for washing. Centrifuge at 
600g for 5 mins at 4
o
C.  
14. Discard supernatant and repeat washing at 450g for 5 mins at 4
o
C. Obtain an 
aliquot for cell counting. Expected cell yield at this stage will be from 1 to 2  
million cells accumulating at the interface per lung. 
15. After washing, discard as much supernatant as possible and obtain a dry cell 
pellet. Disrupt the cell pellet and add Fc block (CD16/CD32) (Biolegend, 
USA) at 0.2µl per 1 million cells. Incubate at 4
o
C for 5 mins. 




16. After incubation, add CD11c-PCP-cy5.5 (Biolegend, USA), CD11b–PE (BD 
Biosciences, USA), CD103-APC (Biolegend, USA) and IAIE-PB (Biolegend, 
USA) to the cells and incubate at 4
o
C for 30 mins. 

















 DCs.  
18. To study the differentiation capacity of DCs, co-culture DCs with either 
freshly-isolated OT-II CD4 T cells from the lymph nodes or lung CD4 T cells 
isolated from respective treatment mice for 4 days. Measure cytokine 
production by ELISA.  
19. To obtain naive CD4 T cells from OT-II mice, first purify CD4 T cells using 
positive selection with CD4 MACS beads as described earlier. 
20. Stain CD4 T cells with CD4-PB (BD pharmingen, USA), CD44-APC (BD 
pharmingen, USA) and CD62L-PE (BD pharmingen, USA). Sort cells using 






 expression.  
 
2.7 Lung histology 
2.7.1 Preparation of lung tissue 
 
1. Inject the mouse with 100µl heparin to prevent blood clotting. 
2. Anesthetize the mouse using 100µl pentobarbital through i.p. injection.  
3. Place the mouse on its back on a rack or paraffin block. 




4. Spread the forelimbs and secure each paw to the rack with a surgical towel 
clamp or a pin if on a paraffin block.  
5. Make a cut along the abdomen to expose the internal organs until the left 
kidney is seen. 
6. Make a cut at the renal artery to deplete circulating blood. 
7. Cut the diaphragm laterally on both sides and cut toward the head across ribs 
and parallel to lungs. The heart is now exposed. 
8. Cut the left atrium to allow blood and perfusion fluid to be released when 
perfusion starts. 
9. With left hand, use a small pair of forceps to grasp ventral tip of the heart. 
10. With right hand, make a small cut at the right ventricle, size enough for the 
cannula tip. 
11. With right hand, insert the cannula and direct it up through the right ventricle 
until the tip of the cannula is visible within the aorta. 
12. Perfuse the lung using a 50ml syringe. Push slowly through the cannula until 
the lung turns pale white.  
13. After perfusion, cannulate the trachea with a needle with plastic tubing and 
push in 0.7ml of 4% Paraformaldehyde or 1% formalin to fix the lung.  
14. Put the perfused and fixed lung tissues in 4% Paraformaldehyde or 1% 
formalin for 2-5 days before processing. 
 




2.7.2 Processing and sectioning of lung tissue 
 
Treat tissues as stated below using the Leica tissue processor: 
1. 75% ethanol 1 hour  
2. 80% ethanol 1 hour 
3. 90% ethanol 1 hour 
4. 100% ethanol 1½ hours 
5. 100% ethanol 1½ hours 
6. 100% ethanol  1½ hours 
7. Histoclear 2 hours 
8. Histoclear 2 hours  
9. Histoclear       2 hours 
10. Wax             2.5 hours 
11. Wax  2.5 hours 
 
2.7.3 Mount tissue in a cassette 
 
1. Transfer tissue from wax to embedding mould. 
2. Place cassette to hold tissue on top of mould. 
3. Top up with enough wax to hold tissue to cassette. 




4. Transfer mould with hot wax and cassette to a cold surface (e.g. ice) and wait 
for wax to solidify. 
5. Remove embedded tissue from mould using a forceps. 







• Slides with paraffin sections 
• Histoclear (Sigma Aldrich, USA) 
• Ethanol (100%, 95% and 70% in distilled water) (Merck, USA) 
• Differentiation solution: acidic ethanol. (0.3% HCl in 70% ethanol) 
• Haematoxylin (Harri’s) (Sigma-Aldrich, USA) 
• Scott’s tap water: 3.5g Sodium carbonate (Na2CO3) and 20g magnesium sulfate 
(MgSO4 * 7H2O)  in 1L distilled water 
• Alcoholic Eosin Y (Sigma-Aldrich, USA) 










Deparaffinize and rehydrate sections as follows: 
1. Histoclear   10 mins 
2. Histoclear   10 mins 
3. 100% ethanol 2 mins 
4. 100% ethanol 2 mins 
5. 95% ethanol 10 dips 
6. 70% ethanol          10 dips 
7. Rinse in distilled Water 
 
For Haematoxylin and eosin staining: (after deparaffinization and rehydration) 
1. Stain in Haematoxylin for 5 mins. 
2. Rinse in distilled Water. 
3. Differentiate in 0.3% acidic ethanol for 30 seconds to 1 minute. 
4. Rinse in distilled water. 
5. Blue in Scott’s tap water for 1 min. 
6. Rinse in distilled Water. 
7. Check under microscope for blue nuclear chromatin. Blue again in scott’s 
tap water if blueing is insufficient and check under microscope again. 
8. Dehydrate in 70% ethanol for 2 mins. 
9. Stain in alcoholic eosin for 30 seconds. 
10. Rinse in 70% ethanol.  
11. Dehydrate and clearing: 




a. 95% Ethanol 10 dips 
b. 100% Ethanol 10 dips 
c. Histoclear  10 mins 
12. Mount the slides with mounting medium. 
Result: 
Nuclear chromatin Blue 
Nucleoli  Visible 
Cytoplasm  Pink – Pink purple 
 
For Periodic acid staining (after deparaffinization and rehydration) 
1. Oxidize in periodic acid solution for 5 mins.  
2. Rinse in distilled Water. 
3. Place in Schiff’s reagent for 15 mins.  
4. Rinse the slides under running tap water for 5 mins. 
5. Counterstain in haematoxylin for 1.5 mins. 
6. wash in tap water.  
7. Dehydrate and clearing: 
a. 70% ethanol    10 dips  
b. 95% ethanol 10 dips 
c. 100% ethanol 10 dips 
d. Histoclear 10 mins 
8. Mount the slides in mounting medium. 
Result: 




Nuclear chromatin Blue 
Nucleoli  Visible 
Mucus  Pink – Pink purple 
 
2.8 Ex vivo CFSE proliferation assay 
 
1. Process the lung as described in “Ex vivo assay of lung parenchymal 
dendritic cells” into single cell suspension. 
2. Layer the cells onto ficoll plaque and spin at 600g for 20mins with minimal 
acceleration and brake.  
3. Collect the interface and resuspend the cells in MACS buffer 
4. Stain cells using CD3-APC (Biolegend, USA), CD8-PE-cy7 (Biolengend, 
USA) and analyse using flow cytometry. 
 
2.9 Intracellular staining of cells for FACS analysis 
 
1. After surface staining, fix and permeabilize cells with 
permeabilization/fixation buffer for 30 mins at 4
o
C. 
2. Wash cells with permeabilization/wash buffer twice. 
3. Stain cells with transcription factors GATA-3, T-bet, foxp3 and RORγt. 
Incubate for 30-45 mins at 4
o
C.  
4. Wash cells with permeabilization/wash buffer twice and re-suspend in FACS 
buffer for immediate analysis or 1% PFA for future analysis. 




2.10 Assessment of airway function 
 
1. Prepare Methacholine (Sigma Aldrich, USA) solution at different 
concentrations. (Concentrations at 0.5, 1, 2, 4, 8mg/ml). 
2. Connect the whole system, the FinePointe™ series RC system (Buxco 
Research System, USA). 
3. Intiate the FinePointe
™
 Review software. 
4. Calibrate the System. 
5. Anesthetize the mouse (one day after the last challenge on day24) with an 
anesthesia cocktail with ketamine (100mg/kg) and medetomidine (15mg/kg) 
obtained from the pharmacy of the animal holding unit by i.p. injection. Wait 
for around 5-10 minutes until there is no reflex. 
6. Perform Tracheotomy, insert the cannula and tie it. 
7. Put the mouse into the chamber and connect the cannula with the metal tube 
of the chamber. 
8. Ventilate the mouse with stroke volume at 200µl/breath and breath frequency 
at 150/min. 
9. Wait for 1-3mins to make sure the breathing of the mouse is synchronized to 
the ventilator. 
10. Click “Recording” and input study name & ID of the mouse and then Press 
“Run”. Record airway resistance (RI) and dynamic compliance (Cdyn). 
11. Inject 10µl PBS with pipette via the aerosol nebulizer.  




12. Immediately press button “OK” (on the FinePointe™ RC system or the 
FinePointe™ software) to start signal recording as soon as the injection is 
finished. 
13. Inject different concentrations of Methacholine solution when the machine 
instruction to load next dosage is initiated.  
14. Take the mouse out from the chamber and sacrifice it by carbon dioxide 
euthanasia. 
15. Dispose the mouse carcasses properly through comparative medicine center. 
16. Save the data and perform analysis on Finepointe™ when the Methacholine 
challenge is over. 
 
2.11 Measurement of cytokines  
 
IL-4, IL-5, IL-10, IL-12, IL-13, IL-17, IFN-γ and eotaxin levels are detected using 
commercially available DuoSet ELISA kits ((R&D systems, USA). 
Plate preparation 
1. Dilute the Capture antibody to the working concentration in PBS without 
carrier protein. Immediately coat a 96-well microplate with 100µL per well of 
the diluted capture antibody. Seal the plate and incubate overnight at room 
temperature. 
2. Aspirate each well and wash with Wash Buffer, repeating the process two 
times for a total of three washes. Wash by filling each well with Wash Buffer 
using a squirt bottle, manifold dispenser or autowasher. Complete removal of 




liquid at each step is essential for good performance. After the last wash, 
remove any remaining Wash Buffer by aspirating or by inverting the plate and 
blotting it against clean paper towels. 
3. Block plates by adding 300µL of Reagent Diluent to each well. Incubate at 
room temperature for a minimum of 1 h. 




1. Add 100µL of sample or standard in Reagent Diluent or an appropriate 
diluents per well. Cover with an adhesive strip and incubate 2 hours at room 
temperature. 
2. Repeat the aspiration/wash as in step 2 of plate preparation. 
3. Add 100µL of the Detection Antibody, diluted in Reagent Diluent, to each 
well. Cover with a new adhesive strip and incubate for 2 hours at room 
temperature. 
4. Repeat aspiration/wash as in step 2 of plate preparation. 
5. Add 100µL of the working dilution of Streptavidin-HRP to each well. Cover 
the plate and incubate for 20 minutes at room temperature. Avoid placing the 
plate in direct light. 
6. Repeat the aspiration/wash as in step 2. 
7. Add 100µL of the substrate solution to each well. Incubate for 20 minutes at 
room temperature. Avoid placing the plate in direct light. 




8. Add 50µL of Stop solution to each well. Gently tap the plate to ensure 
thorough mixing. 
9. Determine the optical density of each well immediately using a microplate 
reading set to 450nm. If wavelength correction is available, set to 540nm or 
570nm, If wavelength correction is not available, subtract readings at 540nm 
or 570nm from the readings at 450nm. This subtraction will correct for optical 
imperfections in the plate. Readings made directly at 450nm without 
correction may be higher and less accurate. 
 
2.12 Measurement of serum immunoglobulins  
 
The same buffer is used in serum immunoglobulin assay except for the coating buffer. 
0.1M sodium carbonate (pH=9.5) is used instead of PBS as coating buffer. (7.13 g 
NaHCO3 and 1.59 g Na2CO3 in 1.0 L distilled water; pH adjusted to 9.5 with 10N 
NaOH.) 
 
Standard ELISA procedures are followed in measuring serum immunoglobulins as 
the measurement of cytokines with some modifications: 
For OVA-specific IgG1, Maxisorb microtiter plates (Nunc, Denmark) are coated with 
10ug/ml OVA (grade V; Sigma Aldrich, Singapore) at 4°C overnight. Monoclonal 
IgG1 antibody (OVA14) is used as the standard and biotinylated rat-anti-mouse IgG1 
heavy chain (Clone number: LO-MG1-2, AbD Serotec, USA) is used as detection 
antibody.  




For OVA-specific IgE, Maxisorb microtiter are coated with unconjugated rat anti-
mouse IgE heavy chain monoclonal antibody (Clone number: LO-ME-3, AbD 
Serotec, USA). Unconjugated mouse OVA monoclonal IgE (Clone number: 2c6, 
AbD Serotec, USA) is used as the standard and biotinylated OVA is used as detection 
antibody.  
 
Total IgE is measured using DuoSet ELISA development kit (R&D systems, USA). 
 
2.13 CTL killing assays 
2.13.1 
51
Cr release assay 
 
The assay is performed under sterile conditions and with complete RPMI media. 
1. Prepare target cells (eg. EL4) in a 15 ml Falcon tube. 
2. Spin down cells at 450g for 5 min at room temperature.  
3. Discard supernatant and add 50 µCi of 
51
Cr in BSL2 cabinet.  
4. Place cells in a 37
o
C incubator with 5% CO2 for 1 hr. 
5. Wash labeled cells with 5 ml of pre-warmed complete RPMI and spin down at 
450 g for 5 mins at room temperature. 
6. Resuspend cell pellet in pre-warmed medium at 1×10
6
 cells/ml concentration. 
Split cells into two 15 ml falcon tubes. Add SIINFEKL peptide (up to 5µM) to 
one of the tubes, and control peptide GP33-41 to the other. Incubate both 
tubes for 30 mins in a 5 % CO2 incubator at 37
 o
C. 




7. Plate effector cells at the desired ratios into a 96-well U-bottomed plate. Eg: 
30:1, 10:1, 3:1, 1:1, 1:3. Add 100µl of pre-warmed medium to wells without 
effector cells. For total lysis controls, add 80 µl of pre-warmed medium with 
20 µl of 10 % Triton-X. 
8. Wash peptide-pulsed target cells with 5 ml of pre-warmed medium at 300g for 
5 mins at room temperature.  
9. Count target cells and resuspend at a concentration of 4 × 10
4
 cells per ml. 
10. Add 100 µl of target cells (4 × 10
3
 per well) to each well in a 96-well U-
bottomed plate. 
11. Incubate plates for 4 to 6 hrs at 37
 o
C /5 % CO2 incubator. 
12. Harvest supernatants from the assay plate using the cell harvester and transfer 
into appropriate wells of 96-well Luma plate.  
13. Dry the Luma plate in oven at 50
 o
C for 2 hrs or O/N at room temperature.  
14. Use Beckman Top Count to make radioactive count. 
 
Cytotoxic activity is defined as %: (sample lysis - spontaneous lysis)/( Total lysis - 
spontaneous lysis) × 100 
Specific lysis % is determined by subtracting the cytotoxic killing of peptide pulsed 
targets versus non-peptide pulsed controls. 
 
2.13.2 CD107α degranulation assay  
 
The assay is performed under sterile conditions and with complete RPMI medium. 




1. Prepare target cells (eg. EL4) in a 15 ml Falcon. 
2. Spin down cells at 450g for 5 min at room temperature.  
3. Wash cells with 5 ml of pre-warmed complete RPMI and spin down at 450g 
for 5 mins at room temperature. 
4. Resuspend cell pellet in pre-warmed medium at 1×10
6
 cells/ml concentration. 
Split cells into two 15 ml falcon tubes. Add SIINFEKL peptide (up to 5 µM) 
to one of the tubes, and control peptide GP33-41 to the other. Incubate both 
tubes for 30 mins in a 5 % CO2 incubator at 37
 o
C. 
5. Plate 100µl effector cells (1×10
6
 cells/ml) into a 96-well U-bottomed plate. 
6. Wash peptide-pulsed target cells with 5 ml of pre-warmed medium at 450g for 
5 mins at room temperature.  
7. Count target cells and resuspend at a concentration of 1×10
6
 cells/ml. 
8. Add 100 µl of target cells to each well (effector cell-loaded) in a 96-well U-
bottomed plate. 
9. Add brefeldin A (BD biosciences, USA) (5µg/ml), monesin (BD biosciences, 
USA) (5µg/ml) and CD107α-APC (ebioscience, USA) (10µg/ml) to each well.   
10. Incubate plates for 4 to 6 hrs at 37
 o
C /5 % CO2 incubator. 
11. Harvest cells and carry out surface staining for CD3 and CD8.  
 




2.14 Genotyping  
Tail Lysis protocol for mouse genotypic DNA isolation  
1. Anesthetize mice with a cocktail of ketamine (100mg/kg) and medetomidine 
(15mg/kg). 
2. Excise a small segment of tail for genotyping.  
3. Add 500µL of Tail Lysis Buffer (100 mM NaCl, 50 mM Tris-HCl (pH 7.9), 
10 mM MgCl2, 1 mM DTT, 1% Triton X-100) with addition of 20µL of 
proteinase K to the tails at 65°C and incubate for 3 hours. 
4. Centrifuge the lysed solution for 10min at 13000g on microcentrifuge. 
5. Transfer the supernatants to a fresh tube and add 1mL of ice-cold absolute 
ethanol to precipitate the genomic DNA. Mix the suspension well by pipetting. 
6. Centrifuge at maximum speed for 10 min. 
7. Discard supernatants and wash the pellet with 1mL of cold 70% ethanol. 
8. Centrifuge at maximum speed for 10 min. 
9. Discard the supernatants and leave the pellet to air-dry. 
10. Dissolve the pellet was dissolved in 1 × TE buffer for subsequent analysis. 
Genotyping of mice via polymerase chain reaction (PCR) amplification 




1. Prepare the reaction for PCR to a final volume of 25uL according to the 
following compostition:   
a. 12.5uL of GoTaq® Green Master Mix (Promega, Wisconsin, USA) 
b. 8.5uL of water 
c. 1uL of DNA template from genotypic DNA isolation via tail lysis 
d. 1.5uL of 5uM forward primer and 1.5uL of 5uM reverse primer 
2. Primers used:  
Primer set A (IFN-γ): Mutant forward (5’- CCT TCT ATC GCC TTC TTG ACG -3’). 
Wild type forward (5’- AGA AGT AAG TGG AAG GGC CCA GAA G – 3’). 
Common reverse  (5’-AGG GAA ACT GGG AGA GGA GAA ATA T-3’). 
 Primer set B (OT-I): Transgene forward (5’- AAG GTG GAG AGA GAC AAA 
GGA TTC - 3’). Transgene reverse (5’- TTG AGA GCT GTC TCC - 3’). Internal 
positive control forward (5’- CAA ATG TTG CTT GTC TGG TG - 3’). Internal 
positive control reverse (5’- AAG GTG GAG AGA GAC AAA GGA TTC - 3’). 
pMC1PolA Neo (5’-GTC AGT CGA GTG CAC AGT TT-3’)  
3. Carry out PCR according to the following setup: 
1. 94°C for 2 min  
2. 94°C for 30 sec  




3. Annealing at 62°C for 15 sec 
4. Extension at 72°C for 2 min 
5. Return to Step 3 for another 29 cycles 
6. Final extension at 72°C for 10 min 
7. Hold at 4°C 
 
2.14 Statistical analysis 
 
Unpaired Student’s t test is used for comparison between two groups and One way 
ANOVA is used for comparison within multiple groups. Data is expressed as mean ± 
SEM (p < 0.05, p < 0.01 and p < 0.001 were indicated). For Flow cytometric profiles 
and histological pictures are representations of repeated experiments.  
 




2.15 List of Antibodies Used 
  
Target Host Clone Conjugation Source 
CCR7 Rat 4B12 PE eBioscience 
CD3 Hamster 500A2 eFluor450 eBioscience 
CD3 Rat 17A2 APC eBioscience 
CD4 Rat RM4-5 PB BD Pharmingen 
CD8α Rat 53-6.7 PB BD Pharmingen 
CD8α Rat 53-6.8 PE-cy7 BD Pharmingen 
CD11b Rat M1/70 PE BD Pharmingen 
CD11c Hamster N418 PerCP Cy5.5 eBioscience 
CD11c Hamster N419 AF647 Biolegend 
CD16/32 Rat 2.4G2 None Biolegend 
CD28 Rat 37.51 PE Biolegend 
CD44 Rat IM7 APC BD Pharmingen 
CD62L Rat HRL1 PE BD Pharmingen 
CD103 Rat  2.00E+07 APC eBioscience 
CD122 Rat TM-β1 PE Biolegend 
CD223 Rat C9B7W APC Biolegend 
Foxp3 Rat FJK-16s APC eBioscience 
Foxp3 Rat FJK-16s PE eBioscience 
GATA3 Rat TWAJ AF647 eBioscience 
Ly-6G Rat 1A8 APC BD Pharmingen 
IA/IE Rat M5/114.15.2 eFluor450 eBioscience 
IA/IE Rat M5/114.15.3 PerCP Cy5.5 eBioscience 
RORγt Rat AFKJS-9 APC eBioscience 
SIINFEKL-H-
2Kb NA NA PE ProImmune 
Siglec-F Rat E50-2440 PE BD Pharmingen 
T-bet Rat ebio4B10 PE BD Pharmingen 
 
 









Asthma is a heterogeneous inflammatory disorder with very complex clinical 
manifestations including airway inflammation, airway hyperresponsiveness and  
symptoms of recurrent wheezing, coughing and shortness of breath (Kim et al., 2010).  
The initiation and progression of asthma have been extensively studied using murine 
models of asthma, which have their own set of parameters for the assessment of 
asthma manifestations including: IgE production, type II cytokine production such as 
IL-4, IL-5 and IL-13, airway and lung parenchymal eosinophilia, goblet cell 
hyperplasia and AHR (Finkelman et al., 2010a; Lewis et al., 2009; McLane et al., 
1998; Webb et al., 2000; Wills-Karp et al., 1998). Mice can be sensitized to various 
foreign antigens, some of which are natural environmental allergens such as house 
dust mite, cockroach extract and ragweed pollen. Although models developed using 
these natural allergens are now being widely used in the studies of asthma 
pathogenesis, OVA-induced asthma remains to be the most common asthma model 
due to the rich resources in gene modified mice and other related diagnostic tools 
which are crucial in the investigation of the involvement of various cell and non-cell 
mediators. Due to the need of T cell receptor transgenic mice, IFN-γ
-/-
 mice and 
commercially available tetramers for the identification of antigen-specific CD8 T 




cells, OVA was chosen as our allergen in this study. While human asthma has at least 
three identifiable components: acute inflammation, chronic inflammation and airway 
remodeling (Bousquet et al., 2000b; Kumar and Foster, 2001b), in this study, we 
focused on the development of acute inflammation and its underlying mechanisms.  
Since variations in the timing and magnitude of the inflammatory responses in acute 
exposure models are quite common and usually related to the choice of antigen, route 
of administration, dose of the antigen as well as the strain of mice (Herz et al., 1996; 
Sakai et al., 1999; Zhang et al., 1997b), throughout our study, we have adopted the 
same immunization and challenge protocol with a consistent route of antigen 
administration as well as consistent and optimized dose of antigen. C57BL/6 mice 
were employed in our investigation as the transgenic mice we needed were available 
on a C57BL/6 background. 
 




3.2 OVA immunization and challenge protocol 
To establish an asthma model, mice were sensitized i.p. with 100µg of OVA 
emulsified in alum at day 0 and boosted on day 14. On days 21 to 23, mice were 
challenged i.n. with 100µg OVA once daily. Mice were then sacrificed and analysis 







Figure 3.2 Immunization and challenge protocol. C57BL/6 mice were primed and 
boosted with 100µg ovalbumin (OVA) emulsified in alum on days 0 and 14 
respectively. Intranasal challenge with 100µg OVA in PBS was given on three 
consecutive days from day 21. Mice were sacrificed 24 hours after the last challenge. 
 
3.3 Increased serum immunoglobulin production in OVA immunized and 
challenged mice 
To evaluate the efficiency of OVA immunization, serum immunoglobulin levels were 
measured using ELISA.  OVA-specific IgE and IgG1 levels were both elevated in the 
0 14 21 22 23 24
OVA/alum  i.p OVA i.n Analysis




OVA-immunized and challenged mice (Fig 3.3). Total IgE level was also increased 















Figure 3.3  Immunoglobulins in the serum of asthma mice. Mice were immunized 
on days 0 and 14 and challenged on days 21-23. Mice were sacrificed on day 24 for 
the collection of samples. Levels of OVA-specific IgE, IgG and total IgE were 
measured by ELISA.  
*
 p < 0.05; 
** 

























































3.4 Increased eosinophil and neutrophil infiltration in the airways in OVA 
immunized and challenged mice 
 The severity of asthma could be partly represented by the abundance of infiltrating 
cells. To overcome the subjectivity of differential cell counting which is solely 
dependent on the morphological properties, antibodies recognizing different cells 
were employed in our study. In the OVA-immunized and challenged mice, the 




) was largely increased in terms of both 
percentage which usually reached above 70% of all the cells in the BAL fluid and 
total cell number which fluctuated around 0.4 × 10
6
 cells (Fig 3.4.1 & Fig 3.4.2). An 




) infiltration (ranged from 2-10% of all cells in 
the BAL fluid) could also be observed as the OVA we used was not endotoxin-free 
(Fig 3.4.1 & Fig 3.4.2). There were more T cells in the BAL fluid in OVA-
immunized and challenged mice which were identified by CD3 (Fig 3.4.2). These 
data suggest that the asthma model we established is robust with significant 
eosinophil and lymphocyte infiltration. Due to the presence of trace endotoxin, 
neutrophil infiltration is also present. 
 
To verify that the markers we used for the differentiation of macrophages, eosinophils 
and neutrophils were sensitive and specific enough to identify these cells, BAL fluid 







cells were mostly macrophages or monocytes with granular nucleus and extensive 




 cells were cells with donut-shaped multi-









 cells were cells with irregular-shaped multi-nuclei and transparent cytoplasm 
which were identified as neutrophils (Fig 3.4.3C). Thus, the markers we employed 















Figure 3.4.1 Infiltration of cells into the airways in response to OVA allergen. 
Mice were immunized on days 0 and 14 and challenged on days 21-23. Mice were 
sacrificed on day 24 for the collection of samples. Cells from the BAL fluid were 

















































Figure 3.4.2 Infiltration of cells into the airways in response to OVA allergen. 
Mice were immunized on days 0 and 14 and challenged on days 21-23. Mice were 
sacrificed on day 24 for the collection of samples. Cells from the BAL fluid were 
stained with CD11c, siglec-F and Ly-6G for flow cytometry analysis. (A) Percentage 
of macrophages, eosinophils and lymphocytes in the BAL fluid. (B) Total number of 
of macrophages, eosinophils and lymphocytes in the BAL fluid. 
*
 p < 0.05; 
** 
p < 0.01. 
(n=5) (One-way ANOVA with Tukey’s Multiple Comparison Test). 
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Figure 3.4.3 Images of sorted BAL fluid cells. Mice were immunized on days 0 and 
14 and challenged on days 21-23. Mice were sacrificed on day 24 for the collection of 
samples. Cells from the BAL fluid were stained with CD11c, Siglec-F and Ly-6G for 
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3.5 Enhanced cell infiltration and mucus production in the lung in OVA 
immunized and challenged mice 
Besides BAL fluid analysis, cell infiltration could also be assessed in the lung tissue 
by hematoxylin and eosin staining. Perfused and fixed lungs were dehydrated and 
sections were cut at 4µm and stained with hematoxylin and eosin. Compared to PBS 
control mice, a lot of infiltrating cells surrounding the airways could be observed in 
OVA-immunized and challenged mice (Fig 3.5A). The airways were also thickened 
compared to the control airways (Fig 3.5A).  
 
Another hallmark for asthma is increased mucus production. Lung tissues were 
similarly prepared as in the hematoxylin and eosin staining. Mucus-producing goblet 
cells were identified with PAS as the pink staining lining inside the epithelial cells. 
Mucus-positive goblet cells could be easily identified in OVA-immunized and 
challenged airways while the control airways were free of positive mucus staining 
(Fig 3.5B).  
 
These images suggest that with OVA immunization and challenge, significant cell 
infiltration and mucus production are evident and the modification of which can be 
used as parameters evaluating the modulating effect of CD8 T cells in our subsequent 
experiments.  




















Fig 3.5 Histological images of H&E and PAS staining of the lung. Mice were 
immunized on days 0 and 14 and challenged on days 21-23. The lungs were perfused, 
fixed and collected one day after the last challenge. Fixed lungs were dehydrated and 
embedded in paraffin, sectioned to 4µm and stained with hematoxylin and eosin or 
periodic acid and schiff’s reagent. (A) Representative histological images of H&E 
staining of lung sections at 20× magnification. (B) Histological images of PAS 











3.6 Increased airway hyperresponsiveness (AHR) in OVA immunized and 
challenged mice 
Although systemic IgE production, local cell infiltration and mucus production are 
very important markers researchers look for in mouse asthma models, AHR is equally 
important and indeed more widely used as a diagnostic tool in identifying human 
asthma for it more accurately reflects on lung function. Using increasing 
concentrations of methacholine (0.5-8mg/ml), airway resistance which was expressed 
as percentage change from baseline could be found to be significantly higher in 
OVA-immunized and challenged mice at various concentrations (Fig 3.6), indicating 
that lung function of these asthma mice was significantly impaired.  















Fig 3.6 Airway hyperresponsiveness following methacholine inhalation. Mice 
were immunized on days 0 and 14 and challenged on days 21-23. To assess AHR, 
mice were heavily anesthetized on day 24 with an anesthesia cocktail of ketamine and 
medetomidine. Airway responsiveness was measured as the change in airway 
resistance (RI) to increased concentration of nebulized methacholine (0.5– 8.0 mg/ml). 
Mice were tracheostomized and mechanically ventilized at a fixed breathing rate of 
140 breaths/min and the airway resistance (RI) were recorded. Results are expressed 
as percentages of respective basal values in response to PBS. 
*
 p < 0.05; 
*** 


































































In this chapter, we have successfully established an OVA-induced asthma model with 
robust serum immunoglobulin production, eosinophil infiltration, mucus production 
and airway hyperresponsiveness. Alum was used as an adjuvant to induce a stronger 
response which would not be achieved by using OVA alone. As OVA with no or very 
low dose of LPS  (0.001µg/ml) was not very effective at inducing allergic responses 
and OVA with high dose of LPS  (100µg/ml) would induce tolerance (Eisenbarth et 
al., 2002a), we chose a batch of commercially available OVA (grade V) with small 
amount of endotoxin (10µg/ml) to help in the establishment of inflammation. 
Meanwhile, due to the presence of endotoxin, infiltration of neutrophils in the BAL 
fluid was also induced. Notably, the IgE level we detected in the serum of OVA 
immunized and challenged mice did not reach a very high concentration as in some 
previous studies. Since our model was established in C57BL/6 mice which are 
believed to be slightly Th1-biased when compared to BALB/c mice, IgE might not go 
up to a comparable level to that seen in BALB/c mice.  
 
To differentiate the different types of infiltrating cells in the BAL fluid, the 
conventional differential counting method has been employed by most of the 
researchers studying asthma (Dubois et al., 2010a; Lambrecht et al., 1998; Stock et al., 
2004b; Takeda et al., 2009b). Differential cell counting is solely dependent on the 
morphological differences among the different immune cells. Other than the potential 
subjectivity during cell counting, it is sometimes very difficult to differentiate 




eosinophils from neutrophils as both have multiple nuclei. Although the cytoplasm 
should appear in different colors, staining might not always work perfectly. It is also 
quite tricky to identify the true lymphocytes from the other mononuclear cells such as 
monocytes and macrophages if the cytoplasm is not well preserved during the 
spinning and staining. Thus, specific antibody staining and flow cytometric analysis 
is a more reliable and objective approach with better resolution. Previously, one 
research group has employed a panel of antibodies (CCR3, Class II, CD11c, CD3, 
B220 and CD3) to identify the BAL fluid cells (Wells et al., 2007b). In our study, we 
used a combination of 4 markers (Siglec-F, Ly-6G, CD11c and CD3) to differentiate 
macrophages, eosinophils, neutrophils and T cells. The combination of Siglec-F and 
CD11c has been shown to be effective in the identification of eosinophils and 
macrophages (Stevens et al., 2007) and Ly-6G is a well known marker for neutrophils. 
(Bao and Cao, 2011; Shi et al., 2011). The staining of the sorted cells based on these 
markers showed that each type of cells was efficiently separated (Fig3.4.3). Thus, we 
have established a robust and reliable staining method to identify BAL fluid cells in 
an asthma model with minimal antibodies and overcomes the subjectivity of the 
conventional differential counting method.  
 
Our model of asthma has the signature features of asthma described for other mouse 
models, but could not replicate all of the morphological and functional lesions of 
human asthma, such as intraepithelial recruitment of eosinophils, chronic 
inflammation and subepithelial fibrosis. (Kumar and Foster, 2001a). Moreover, the 
presence of airway hyperresponsiveness does not equal asthma and the methodology 




to assess airway reactivity in animal models and human asthma is quite different 
(Kumar and Foster, 2001a). Nevertheless, this model serves as a useful tool to dissect 
the mechanisms in the induction of airway inflammation and mucus production.  




CHAPTER 4: Phenotypic characterization of in-vitro activated CD8 T cells and 
their recruitment into OVA-immunized mice 
 
4.1 Introduction 
In Chapter 3, we have established a robust asthma model using OVA as the allergen 
and alum as the adjuvant. With this model, we now could investigate the regulatory 
role of CD8 T cells in the pathogenesis of asthma. The involvement of IFN-γ 
production by CD8 T cells was of particular interest.  
 
To focus on the role of IFN-γ in the modulating effect of CD8 T cells, we aimed to 
generate transgenic mice with CD8 T cells specifically recognizing OVA peptide but 
not producing IFN-γ by cross breeding OT-I and IFN-γ
-/-
 mice. As naïve CD8 T cells 
preferentially traffic to peripheral lymph nodes while activated effector CD8 T cells 
get recruited to the inflamed peripheral tissues more efficiently (Nolz et al., 2011a), 
effector cells were used in our study to ensure that these cells could be recruited to the 
site of inflammation and interfere with the inflammatory process.  
 
As the silence of an important gene always leads to complicated consequences, the 
inhibition of IFN-γ in the OT-I mice might also lead to significant changes in the 
phenotype of CD8 T cells. Therefore, a phenotypic comparison between OT-I and 
IFN-γ
-/-
OT-I CD8 T cells is essential. Cells at both naïve and activated stages were 
thus compared. 









OT-I mice, OT-I mice were cross bred with IFN-γ
-/-
 mice. If we 
assign T for OT-I transgenic gene, t for wild type gene and G for wild type IFN-γ 
gene, g for IFN-γ
-/-
 gene, OT-I mice would have the genotype of TGG as OT-I mice 
are hemizygous and IFN-γ
-/-
 mice would be ttgg, The F1 generation will be 
heterozygous with the genotype of TtGg. These heterozygous mice were mated with 
each other and the F2 generation comprised mice with different genotypes including: 
TTGG, TTGg, TTgg, TtGG, TtGg, Ttgg, ttGG, ttGg and ttgg. Mice with genotypes 
TTgg and Ttgg were chosen and further bred until we could get a high percentage of 
mice with the TCR transgene but not IFN-γ. Candidate mice were genotyped to 
ensure that they had the TCR transgene which was identified as a 300bp band and an 
internal positive control band at 200bp according to Jackson laboratory’s manual. 
Meanwhile, positive results could also be reflected in a flow cytometric plot via the 
expression of Vα2 and Vβ5 genes. Genotyping was also carried out to assess whether 
the candidate mice were indeed IFN-γ
-/-
. Wild type mice give a band with size of 
260bp while the IFN-γ
-/-
 mice with neomycin insertion give a band at 320bp.  
 
To find out the TCR gene expression using flow cytometry, blood was collected and 
the cells were stained with CD3, CD8, Vα2 and Vβ5. Single cells were selected at 
low pulse width (Fig 4.2A upper left panel) and cells with small size and low 
granularity were then chosen (Fig 4.2A upper middle panel). CD8 T cells were gated 
on (Fig 4.2A upper right panel) and those with high percentage of Vα2 and Vβ5 co-




expression were selected for either final usage or further breeding (Fig 4.2A lower 
panel). To further confirm the mice were authentic, genotyping was also carried out. 
All the candidate mice (lanes 2-6) expressed the transgenic TCR gene with band size 
320bp and the internal positive control band 200bp (Fig 4.2B). The expression of 
IFN-γ gene was also verified by genotyping. Only mouse 1 (Lane 2) had the same 
320bp band as in the IFN-γ
-/-
 control indicating it was a homozygous IFN-γ
-/-
 mouse 
(Fig 4.2C). Mice 2-4 (Lanes 3-5) were heterzygous as 2 bands (320bp and 260bp) 
could be observed (Fig 4.2C). Mouse 5 (Lane 6) on the other hand, had 2 alleles both 
expressing the IFN-γ gene indicated by the single 260bp band (Fig 4.2C). Thus, 
mouse1 was the only authentic IFN-γ
-/-
OT-I mouse in this batch. Similar seletion 






















































Fig 4.2 Breeding and selection of IFN-γ
-/-
OT-I mice. To generate IFN-γ
-/-
OT-I mice, 
OT-I mice were cross-bred with IFN-γ
-/-
 mice. F1 generation was used to further 
cross-bred and the F2 generation was genotyped and also analyzed by flow cytometry. 
Mice expressing the transgenic TCR gene but not IFN-γ gene were selected. (A) Flow 
cytometric analysis of one candidate mouse for the expression of transgenic TCR 
gene Vα2 and Vβ5. (B) Genotyping of candidate mice for the expression of 
transgenic TCR gene. (C) Genotyping of candidate mice for the expression of IFN-γ 
gene. (Data courtesy from Benson, YL Chua). 




Lanes 1&11: 100bp Ladder
Lanes 2-6: Samples 1-5
Lane 7: C57BL/6 (+/+)
Lane 8: C57BL/6×IFN-γ-/-(+/-)








Lanes 1&10: 100bp Ladder
Lanes 2-6: Samples 1-5
Lane 7: OT-I (+/-)
Lane 8: C57BL/6 (-/-)
Lane 9: Water




4.3 Effector phenotype of activated CD8 T cells 
Our pilot study showed that naive CD8 T cells were recruited poorly into the lung 
following OVA challenges as shown in section 4.9 (Fig 4.9E). In this study, we used 
activated CD8 T cells which were more efficiently recruited (data shown later in Fig 
4.9) and thus expected to have more direct effect on asthma. It is then important to 
characterize the activated cells in order to understand the mechanism of their action. 




CD8 T cells were in vitro stimulated with 
PMA and ionomycin for 48h before phenotypic analysis and adoptive transfer. A 
series of markers were examined including activation markers CD28, CD44, CD122 
and CD223, central memory marker CCR7 and CD8 regulatory marker CD103. We 




CD8 T cells expressed high levels of activation 
markers CD28, CD44 and CD223 without any significant increase in CCR7 or 
CD103 (Fig 4.3). CD122 expression was slightly upregulated with only a small 
percentage of the cells expressing high levels of CD122. These data suggest that after 
in vitro stimulation with PMA and ionomycin, CD8 T cells assume an activated 












































































Fig 4.3 Surface marker expression of CD8 T cells after in vitro stimulation.  CD8 





in vitro stimulated with 10ng/ml PMA and 400ng/ml ionomycin for 48 hours and 
stained with various surface markers, including CD28, CD44, CD122, CD223, CCR7 
and CD103. Representative FACS plots are shown. (n = 5) 
 




4.4 Differential transcription factor expression of activated CD8 T cells 





mice, transcription factors for type I, II, 17 and regulatory T 
cells were stained and compared. Strikingly, OT-I CD8 T cells had much higher T-bet 
expression (11-fold increase) after stimulation while IFN-γ
-/-
OT-I CD8 T cells had 
less than 2-fold increase (Fig 4.4), indicating that OT-I CD8 T cells were more Tc1-
biased but IFN-γ
-/-
OT-I CD8 T cells were not. On the contrary, the expression of 
RORγt increased more in IFN-γ
-/-
OT-I (8.9-fold increase) than OT-I CD8 T cells (6.3-
fold increase) (Fig 4.4). GATA-3 and Foxp3 remained relatively low in both OT-I and 
IFN-γ
-/-
OT-I CD8 T cells. Notably, IFN-γ
-/-
OT-I CD8 T cells had a slight increase in 
the expression of GATA-3 (2-fold) while the increase in OT-I CD8 T cells was less 
significant (1.3-fold) (Fig 4.4). Together, these data suggest that following the 
stimulation with PMA and ionomycin, OT-I CD8 T cells exhibit a Tc1-like phenotype 
with some Tc17 properties and IFN-γ
-/-
OT-I CD8 T cells are more Tc2/Tc17 biased.  


















Fig 4.4 Transcription factor expression of CD8 T cells after in vitro stimulation.  





were in vitro stimulated with 10ng/ml PMA and 400ng/ml ionomycin for 48 hours 
and stained with transcription factors, including T-bet, GATA-3, RORγt and Foxp3. 





Activated OT-IxIFN-γ-/- MFI: 48
Naïve OT-I MFI: 19
Naïve OT-IxIFN-γ-/- MFI: 27
Activated OT-I MFI: 210
Activated IFN-γ-/-OT-I MFI: 6.5
Isotype MFI: 3.5
Activated OT-I MFI: 5.5
Naïve OT-I MFI: 4.1






Activated IFN-γ-/-OT-I MFI: 169
Isotype MFI: 3.5
Activated OT-I MFI: 139
Naïve OT-I MFI: 22











Activated OT-I MFI: 4.1
Activated IFN-γ-/-OT-I MFI: 3.5
Naïve OT-I MFI: 2.6






















4.5 Cytokine production by activated CD8 T cells 
To find out whether cytokine production profile was consistent with transcription 
factor expression, the supernatant was harvested after the 48-hour stimulation and 
analyzed by ELISA. As expected, IFN-γ was the predominant cytokine produced by 
OT-I CD8 T cells (Fig 4.5). Although IL-17 was also found in the supernatant, it was 
present at a much lower concentration (approximately 1/30 of the concentration of 
IFN-γ) (Fig 4.5). This corresponded with the largely elevated expression of T-bet and 
a less profound increase in RORγt.  No obvious increase in type II cytokines was 




CD8 T cells, on the other 
hand, produced high levels of both IL-13 and IL-17 (Fig 4.5), which again was 
consistent with the increased expression of GATA-3 and RORγt. These data suggest 




CD8 T cells produce very different cytokines which 
correspond well with their transcription factor expression. While IFN-γ-producing 




CD8 T cells are more Tc2/Tc17 
like and produce more IL-13 and IL-17. 
 
















Fig 4.5  Cytokine production by CD8 T cells after in vitro stimulation.  CD8 T 





in vitro stimulated with 10ng/ml PMA and 400ng/ml ionomycin for 48 hours. 












































4.6 Distinct cytotoxicity properties of activated CD8 T cells 
Since IFN-γ can be involved in cytotoxicity, we then looked into the cytotoxic 




CD8 T cells, both naive and activated. Interestingly, 





cells when incubated with SIINFEKL peptide-loaded target cells (EL4), reflected by 
the accumulation of CD107α on cell surface (Fig 4.6A). Consistently, 
51
Cr release 




CD8 T cells were poorer killers when compared 
to OT-I CD8 T cells (Fig 4.6B). Since the cells we used for adoptive transfer were the 
activated one, 
51
Cr release assay was also used to determine the cytotoxic property of 









CD8 T cells became 





CD8 T cells after activation (Fig 4.6C). These data 




CD8 T cells both 
when naive and activated and both become less cytotoxic upon activation. 




















Fig 4.6 Cytotoxicity of naive and effector CD8 T cells.  (A) To study the 
cytotoxicity of naive CD8 T cells via CD107α assay, freshly-isolated CD8 T cells 




mice were incubated with peptide-pulsed target cells (EL4) 
for six hours in the presence of monesin, brefeldin-A and CD107α. Cells were then 
harvested and stained with CD3 and CD8.  (B) To study the cytotoxicity of naive 
CD8 T cells via 
51





mice were incubated with peptide-pulsed and 
51
Cr-labeled target cells 
B






























































































































































































(EL4) at designated ratios for six hours. Supernatant was then harvested and 
transferred to a Luma plate for drying. Radioactive counts were then determined. (C) 
To study the cytotoxicity of activated CD8 T cells via 
51
Cr release release assay, 




mice were stimulated in vitro 
with 10ng/ml PMA and 400ng/ml ionomycin for 48 hours. Effector cells were then 
washed and incubated with peptide-pulsed and 
51
Cr-labeled target cells (EL4) at 
designated ratios for six hours. Supernatant was then harvested and transferred to a 






p<0.001. (n=4). (Student’s t-test). 




4.7 Similar proliferation index of OT-I and IFN-γ
-/-
OT-I CD8 T cells 




CD8 T cells would proliferate 
differently since they differ significantly in their phenotype, freshly isolated CD8 T 
cells were labeled with violet CFSE before in vitro stimulation with PMA and 
ionomycin. Although 48-hour stimulation was used for the generation of activated 
cells for adoptive transfer, 64-hour stimulation was used instead in this proliferation 
experiment because we would like to get more daughter generations for a better 
comparison.  All the CD8 T cells labeled with CFSE and fixed at time zero had very 
high levels of CFSE expression indicating that these cells have not started replicating 
yet (Fig 4.7A). After 64 hours, multiple peaks were present and each represented one 
different generation (Fig 4.7B). The lower the CFSE expression, the more cycles the 




CD8 T cells, the same 
numbers of daughter generations were found and no obvious difference in the 
percentages of cells in each generation could be observed. These data suggest that 





CD8 T cells proliferate similarly under in vitro stimulation. 
 














Fig 4.7 CFSE proliferation of CD8 T cells. Freshly-isolated CD8 T cells were 
labeled with violet CFSE before culture in the presence of 10ng/ml PMA and 
400ng/ml ionomycin. Cells were harvested after 64 hours and stained with CD3 and 
CD8. For naive control, freshly-isolated cells were labeled with violet CFSE, stained 
with CD3 and CD8 at 0-hour and fixed in 1% PFA. Each peak represents a daughter 
generation.  (A) CFSE expression of naive CD8 cells at 0 hour. (B) CFSE expression 





















4.8 CD8 T cell transfer protocol 
After the thorough characterization of OT-I and IFN-γ-deficient OT-I CD8 T cells, 
we then performed adoptive transfer. 3 × 10
6





cells were transferred into OVA-immunized mice one day before the intranasal 
challenges commenced (Fig 4.8). This was referred to as elicitation or effector phase 
intervention. Immunization and challenges remained identical as in the asthma model.  
 
 
0 14 20 21 22 23 24
OVA/alum i.p OVA i.n




Fig 4.8 CD8 T cell adoptive transfer protocol. C57BL/6 mice were primed and 
boosted with 100µg OVA emulsified in alum on days 0 and 14 respectively. Adoptive 
transfer of 3 × 10
6




CD8 T cells was carried out on day 
20, one day before intranasal challenged started. Intranasal challenge with 100µg 
OVA in PBS was given on three consecutive days from day 21. Mice were sacrificed 
24 hours after the last challenge. 
 




4.9 Efficient recruitment of effector CD8 T cells into the lungs of sensitized mice 
Transfer of 3 × 10
6
 OT-I or IFN-γ
-/-
OT-I CD8 T cells into OVA-sensitized mice was 
carried out prior to three daily OVA intranasal challenges (Fig 4.2.6). OVA-specific 
CD8 T cells in the lung parenchyma were detected using H2K
b
/SIINFEKL tetramer. 
Significant numbers (4%) of tetramer-positive cells were detected in OVA-immunized 
and challenged mice (Fig 4.9A&B) suggesting that CD8 T cell response was also 
triggered in addition to CD4 T cells in the course of asthma induced by OVA. 
Following the transfer of either effector OT-I or IFN-γ
-/-
OT-I CD8 T cells, the 
percentage of SIINFEKL
+
 CD8 T cells in the lung was largely increased (7-fold, 
around 30%), indicating efficient recruitment of these cells (Fig 4.9A&B). No 
significant difference was found between the two groups of adoptive transfer 




 CD8 T cells were also found to be efficiently 
recruited into the alveolar spaces as measured in the BAL fluid (Fig 4.9C). As 
expected, CD8 T cells did not traffic to the lung draining mediastinal lymph nodes as 










 CD8 T cells detected were due to recruitment. These transferred 
cells were still proliferating which will be shown in the next section. Thus, these data 
suggest that effector CD8 T cells are recruited to the site of inflammation very 
efficiently, regardless of IFN-γ. 
 
 













































































































































































































































































































Fig 4.9 Recruitment of effector CD8 T cells following adoptive transfer. Mice 
were immunized on days 0 and 14, adoptively transferred with effector (or naive) 
CD8 T cells on day 20 and challenged on days 21-23. Lung parenchymal cells were 
obtained one day after the last challenge. OVA-specific CD8 T cells were identified 
by H-2K
b




















 CD8 T cells in the mediastinal lymph nodes. (E) 




 CD8 T cells in the lung of naive or 
activated CD8 T cell-transferred mice.
 +
 p<0.05 (compared with PBS/PBS group); 
*
 
p<0.05 (compared with OVA/OVA group); 
**
 p<0.01. (n=8). (One-way ANOVA 
with Tukey’s Multiple Comparison Test). 
E 




4.10 Similar in vivo proliferation rate of transferred CD8 T cells 





cells was similar, in vivo proliferation influenced by the microenvironment might be 
different. Thus, effector CD8 T cells were labeled with violet CFSE prior to adoptive 
transfer and retrieved from the lung parenchyma after OVA challenge. Two different 
time points 48 hours and 96 hours post transfer were chosen to enable a thorough 
comparison. SIINFEKL
- 





CD8 T cells proliferated at similar rate both at 48-hour (Fig 
4.10A) and 96-hour (Fig 4.10B) time points. At 48 hours, majority of the cells (>90%) 
have proliferated at least once. By 96 hours, majority of the cells have proliferated 
multiple times and the CFSE signal could hardly be detected (low MFI) (Fig 4.10C).  
Notably, the daughter peaks in this experiment differ from the distinct peaks observed 
with in vitro proliferation. This might be due to the different starting points as the 
cells had already undergone activation in vitro and the heterogeneous signals 
available in the microenvironment in vivo might make synchronized proliferation 
impossible. These data demonstrate that both types of cells recruited to the lung 
parenchyma continue to proliferate at similar rates, regardless of IFN-γ. 





MFI: 1.0 MFI: 1.0
SIINFEKL-CD8 control SIINFEKL-CD8 control
OT-I IFN-γ-/-OT-I
90 10 92 8
99 1 99 1
 
 
Fig 4.10 In vivo proliferation of transferred CD8 T cells. Mice were immunized on 
days 0 and 14, adoptively transferred with CFSE-labeled effector CD8 T cells on day 
20 and challenged on day 21 or days 21-23. Lung parenchymal cells were harvested 
one day after the last challenge. Two time points were chosen for the study on CD8 T 
cell proliferation: 48 and 96 hours. (A) SIINFEKL
-
 CD8 T cells as negative control 
for CFSE labeling. (B) CFSE proliferation of transferred CD8 T cells 48 hours post 










In this chapter, we have described the generation of IFN-γ
-/-
OT-I mice and the 
phenotypic comparison between OT-I and IFN-γ
-/-
OT-I CD8 T cells. Both types of 
cells expressed similar surface markers but OT-I CD8 T cells were more Tc1-biased 
while IFN-γ
-/-
OT-I CD8 T cells were more Tc2/Tc17-biased based on transcription 
factor expression. Cytokine production profiles were also different that OT-I CD8 T 
cells dominantly produced IFN-γ while IFN-γ
-/-
OT-I CD8 T cells produced IL-13 and 
IL-17. Both types of cells proliferated at similar rates and were recruited to the site of 
inflammation equally efficiently. Interestingly, both naïve and activated OT-I CD8 T 
cells were more cytotoxic than IFN-γ
-/-
OT-I CD8 T cells. 
 
Most studies investigating the role of IFN-γ use CD8 T cells isolated from immunized 
IFN-γ
-/-
 mice (Dubois et al., 2010b; Takeda et al., 2009b), which usually have either 
poor antigen-specificity or a limited number of cells. Alternatively, antisense oligo-
deoxynucleotide or blocking antibody is used to neutralize IFN-γ in the mice which 
causes systemic effect (Isogai et al., 2007; Polte et al., 2007). To overcome these 









OT-I CD8 T cells expressed similar surface markers to OT-I CD8 T cells after 
activation with high expression of various markers, including the co-stimulatory 
molecule CD28, the cell adhesion molecule and activation marker CD44  (Johnson 




and Ruffell, 2009), IL-2 receptor CD122 and lymphocyte activation gene-3 (CD223). 
Low/no expression of CD8 regulatory marker CD103 (Uss et al., 2006) or central 
memory marker chemokine receptor CCR7 (Schaeuble et al., 2011) was observed. 
CD122
+
CD8 T cells have also been identified as regulatory cells (Dai et al., 2010) 
which could produce IL-10 and suppress IFN-γ production (Endharti et al., 2005). 
The different levels of CD122 expression were also shown to favor either CD8 central 
memory or effector memory cell development, with stronger expression favoring 
effector memory cells (Castro et al., 2011). CD223 is expressed on activated T cells, 
binds to MHCII at a very high affinity and was shown to negatively regulate T cell 
expansion and control the size of memory pool (Workman et al., 2004). Since we 
could exclude the possibility of these activated CD8 T cells as regulatory or central 
memory cells based on their expression of CD103 and CCR7, these cells could be 
identified as effector cells due to the high expressions of CD28, CD44 and CD223. 
CD44 in particular, is very important in the migration and recruitment of effector T 
cells to the site of inflammation (Johnson and Ruffell, 2009). A very small population 
of these CD8 T cells expressed a high level of CD122, which were supposed to be the 
regulatory cells. Majority of the CD8 T cells had intermediate expression of CD223 
which were most probably effector cells.   
 
Expression of transcription factors showed that OT-I CD8 T cells were Tc1-biased 
cells with some RORγt up-regulation while IFN-γ
-/-
OT-I CD8 T cells were Tc2/Tc17-
biased with low T-bet. Cytokine production in the supernatant of culture corresponded 
well with transcription factor expression that OT-I CD8 T cells predominantly 




produced IFN-γ with some production of IL-17, the level of which was much lower 
than IFN-γ and IFN-γ
-/-
OT-I CD8 T cells predominantly produced IL-13 and IL-17 at 
comparable levels. The absence of IFN-γ might have triggered some compensation 
mechanisms through which IFN-γ
-/-
OT-I CD8 T cells become potent producers of 
other cytokines.  The differences in subtype-bias and cytokine production might 
contribute significantly in the regulatory effect of the CD8 T cells as we will discuss 
in the next chapter. Interestingly, the cytotoxicity of IFN-γ
-/-
OT-I CD8 T cells became 
weaker than OT-I CD8 T cells at both naïve and activated stages. Our finding is in 
line with previous studies (Liao et al., 2011; Refaeli et al., 2002; Schoenborn and 
Wilson, 2007; van Besouw et al., 2009) which showed that there is a correlation 
between IFN-γ and cytotoxic killing and that IFN-γ is involved in the enhancement of 
cytotoxicity. On the other hand, Tc17 cells were shown to lack the classic cytotoxic 
function based on their granzyme B and perforin secretion as well as lytic capability 
(Yen et al., 2009) and Tc2 were shown to be less effective in tumor immunotherapy 
due to their weaker cytotoxicity compared to Tc1 cells (Ye et al., 2007). Thus, it was 
not surprising that IFN-γ
-/-
OT-I CD8 T cells which displayed a Tc2/Tc17 phenotype 
and lack IFN-γ production were weaker killers than OT-I CD8 T cells. However, in 
contrast to tumor immunotherapy, investigation of the involvement of CD8 T cell 
cytotoxicity in models of asthma has not been very active and little is known for this 
aspect. 
 




In contrast to some previous studies where CD8 T cells were transferred before 
immunization, adoptive transfer in our study was performed after immunization, at 
the elicitation phase.  This approach is clinically more relevant with respect to 
vaccine development as the prediction of initial allergen exposure is difficult and it is 
thus more practical to commence CD8 T cell transfer therapy after sensitization to the 
allergen. Effector cells were given one day before the challenges started and as 
expected, efficient recruitment of these cells was observed in the lung parenchyma 
and airways but not in the mediastinal lymph nodes. These recruited cells continued 
to proliferate and at similar rates as shown in Fig 4.10. Since all the daughter cells 
will recognize the same peptide (SIINFEKL) as well, it is hard to differentiate the 
exact percentage of recruited cells and the percentage of cells due to proliferation. 
However, since both types of cells proliferate at similar speed, finding out the ratio of 











CHAPTER 5: Effector OT-I but not IFN-γ
-/-





The role of CD8 T cells in asthma remains controversial despite the intensive 
research been done over the past few decades. Constant debate is going on in this 
field of research on the contribution of CD8 T cells in asthma: beneficial or 
deleterious. CD8 T cells were shown to exist in two different subsets, namely Tc1 and 
Tc2 (Croft et al., 1994a; Noble et al., 1995; Seder et al., 1992) and contribute to the 
pathogenesis of asthma very differently. While pro-inflammatory Tc2 subtype 
predominates in the lungs of asthmatic patients and is always associated with 
exacerbation of asthma (Cho et al., 2005; Meissner et al., 1997; Sawicka et al., 2004; 
Schaller et al., 2005; Stock et al., 2004a; Ying et al., 1997), Tc1 cells can superimpose 
a Th1-biased inflammation over Th2 response and are capable of suppressing Th2 
inflammation, especially if present prior to sensitization (Ishimitsu et al., 2001; Wells 
et al., 2007a). IFN-γ from CD8 T cells was shown to play an important role in the 
attenuation of allergic lung inflammation (Huang et al., 1999; Suzuki et al., 2002; 
Suzuki et al., 1999; Takeda et al., 2009a) though the underlying mechanisms remain 
unclear. Recently, a new subset of CD8 T cells Tc17 was also described (Intlekofer et 
al., 2008) and IL-17 produced by these cells was shown to be pro-inflammatory in 
pulmonary pathology (Yen et al., 2009). In addition, the effector and memory status 




of CD8 T cells may also be crucial in influencing their regulatory effects with the 
effector phenotype exhibiting a strong bias toward promotion of allergic responses 
(Miyahara et al., 2004a; Taube et al., 2006).  
 
In the previous chapter, a thorough phenotypic characterization of the activated CD8 
T cells were carried out and these CD8 T cells were identified as effector cells. OT-I 
CD8 T cells were more potent in IFN-γ production and IFN-γ
-/-
OT-I CD8 T cells were 
better producers of IL-13 and IL-17. Cytotoxic activity of IFN-γ
-/-
OT-I CD8 T cells 
was also found to be weaker than OT-I CD8 T cells. In this chapter, we aim to find 
out how these cells with different properties would interfere with the Th2 
inflammatory process differently when they are transferred at the elicitation phase of 
our asthma model.  
 
 




5.2 Unchanged serum immunoglobulin production in response to CD8 T cell 
transfer 
To evaluate whether transfer of CD8 T cells could lead to systemic change in the 
production of immunoglobulins, serum was collected one day after the last challenge 
and OVA-specific IgE and IgG levels were detected using ELISA. Consistently, 
OVA immunization and challenge led to the production of large amounts of OVA-
specific IgE and even more IgG1 (Fig 5.2). Following the transfer of either OT-I or 
IFN-γ
-/-
OT-I CD8 T cells, the levels of OVA-specific IgE and IgG1 were not 
significantly altered (Fig 5.2). These data suggest that transferred at the effector phase, 









Fig 5.2 Immunoglobulins in the serum in response to CD8 T cell transfer.  Mice 
were immunized on days 0 and 14, adoptively transferred with effector CD8 T cells 
on day 20 and challenged on days 21-23. Serum was collected one day after the last 
challenge. OVA-specific IgE and IgG1 were measure using ELISA. 
++
 p<0.01 












































































5.3 Altered cytokine and chemokine production in the bronchoalveolar lavage in 
response to CD8 T cell transfer 
Following the transfer of OT-I or IFN-γ
-/-
OT-I CD8 T cells which were potent 
producers of IFN-γ or IL-13 and IL-17 respectively, we would like to find out 
whether the microenvironment was changed in the airways. Bronchoalveolar lavage 
was collected and the supernatant was tested for the presence of various cytokines as 
well as the chemoattractant for eosinophils: eotaxin. No significant difference was 
observed for the production of IL-4, IL-5, IL-10 and IL-13 (Fig 5.3). IFN-γ level was 
largely elevated in mice with the transfer of OT-I but not IFN-γ
-/-
OT-I CD8 T cells 
(Fig 5.3). Interestingly, eotaxin level was only significantly higher in mice with the 
transfer of IFN-γ
-/-
OT-I CD8 T cells when compared to the PBS control mice (Fig 
5.3). These data suggest that the recruitment of potent cytokine-producing CD8 T 
cells altered the microenvironment in the asthma mice which might play a role in the 
modulation of asthma symptoms.  


















Fig 5.3 BAL cytokine and chemokine production in response to CD8 T cell 
transfer.  Mice were immunized on days 0 and 14, adoptively transferred with 
effector CD8 T cells on day 20 and challenged on days 21-23. BAL fluid was 
collected one day after the last challenge. Type I cytokine IFN-γ, type II cytokines IL-
4, IL-5, IL-10 and IL-13 as well as chemoattractant eotaxin in the supernatant of the 
BAL fluid were detected using ELISA. 
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5.4 Inhibition of eosinophil infiltration by OT-I CD8 T cells and enhancement of 
eosinophil and neutrophil infiltration by IFN-γ
-/-
OT-I CD8 T cells  
As cell infiltration especially eosinophilia is an important hallmark for asthma and we 
have shown in the previous section that the microenvironment in the airways was 
significantly changed, the next parameter we used to evaluate the effect of CD8 T 
cells on asthma was the infiltrating cells retrieved in the bronchoalveolar lavage fluid. 
These cells were stained with Siglec-F, CD11c, Ly-6G and CD3, similar to the 
combination of antibodies we used in developing the asthma model. Consistently, 
eosinophil infiltration was profound in OVA immunized and challenged mice (Fig 
5.4).  Due to the presence of endotoxin, neutrophils were also present in the fluid 
although in much lower percentage than eosinophils (Fig 5.4). Upon the transfer of 
OT-I CD8 T cells, the percentage and total number of eosinophils in the BAL fluid 
were significantly reduced which was not observed in mice with the transfer of IFN-γ
-
/-
OT-I CD8 T cells (Fig 5.4). Indeed, although the percentage of eosinophils in mice 
with the transfer of IFN-γ
-/-
OT-I CD8 T cells was not significantly different from the 
asthma mice (Fig 5.4), due to the increase in the total cell number in the BAL fluid 
following CD8 transfer, the absolute number of eosinophils in these mice was much 
higher than in the asthma mice (Fig 5.4B). Neutrophil infiltration was enhanced in 
mice with both OT-I and IFN-γ
-/-
OT-I CD8 T cell transfer in terms of both percentage 
and absolute cell number (Fig 5.4). This could be a result of the cytokines produced 
by the transferred CD8 T cells which will be discussed later. T lymphocyte 
infiltration was also exacerbated in mice with both OT-I and IFN-γ
-/-
OT-I CD8 T cell 




transfer (Fig 5.4), which was mostly likely due to the recruitment of transferred CD8 
T cells.  
 
Together, these data suggest that effector OT-I CD8 T cells are able to alleviate the 
infiltration of eosinophils while IFN-γ
-/-
OT-I CD8 T cells exacerbate eosinophilia 
when administered at the elicitation phase. Transfer of both types of CD8 T cells 
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Fig 5.4. Infiltration of granulocytes in the BAL in response to CD8 T cell 
transfer.  Mice were immunized on days 0 and 14, adoptively transferred with 
effector CD8 T cells on day 20 and challenged on days 21-23. BAL fluid was 
collected one day after the last challenge. BAL cells were stained with Siglec-F, 
CD11c, Ly-6G and CD3 and analyzed by flow cytometry. (A) Representative FACS 
plots for eosinophils, neutrophils and macrophages in the BAL for different treatment 
groups. (B) Summarized results and statistical analysis for macrophages, eosinophils, 
neutrophils and T lymphocytes in the BAL both in terms of percentage (left) and 
absolute cell number (right). 
+





p<0.05 (compared with OVA/OVA group);
 **
 p<0.01. (n=8). (One-way ANOVA with 

























































































































5.5 Reduced mucus secretion in the lung in response to OT-I CD8 T cell transfer 
We have shown in the previous section that cell infiltration was attenuated by OT-I 
CD8 T cells but exacerbated by IFN-γ
-/-
OT-I CD8 T cells. Next, we would like to 
investigate the role of these CD8 T cells on mucus production. Lung sections were 
prepared similarly to hematoxylin and eosin staining. Perfused and fixed lungs were 
dehydrated and sectioned to 4µm and stained with periodic acid and schiff’s reagent. 
Mucus-producing goblet cells were identified as the pink staining lining inside the 
epithelial cells. OVA immunization and challenge induced large amount of mucus 
producing cells which was slightly attenuated by the transfer of OT-I but not IFN-γ
-/-
OT-I CD8 T cells (Fig 5.5). Airway thickening could be observed in all the groups 
expect for the PBS control (Fig 5.5A). These data suggest that the transfer of OT-I 
CD8 T cells successfully alleviates mucus production which the transfer of IFN-γ
-/-
OT-I CD8 T cells fails to achieve. 
PBS/PBS OVA/OVA
OVA/OT-I/OVA OVA/IFN-γ-/-OT-I/OVA
A 200µm 200µm 
200µm 200µm 















Fig 5.5 Mucus production in response to CD8 T cell transfer.  Mice were 
immunized on days 0 and 14, adoptively transferred with effector CD8 T cells on day 
20 and challenged on days 21-23. The lungs were perfused, fixed and collected one 
day after the last challenge. Fixed lungs were dehydrated and embedded in paraffin, 
sectioned to 4µm and stained with periodic acid. (A) Representative histological 
images were shown for different treatment groups at 10 and 40× magnifications. (B) 
Scored analysis of PAS-positive areas. 
++
 p<0.01 (compared with PBS/PBS group); 
*
 
p<0.05 (compared with OVA/OVA group). (n=5). (One-way ANOVA with Tukey’s 






























































5.6 Persistent airway hyperresponsiveness following CD8 T cell transfer 
Since cell infiltration and mucus production were significantly attenuated by the 
transfer of OT-I CD8 T cells, it was then important to find out whether airway 
hyperresponsiveness was also modulated by these CD8 T cells as lung function is 
most commonly assessed by airway hyperresponsiveness in clinical settings. To 
assess lung function of treated mice, airway hyperresponsiveness was measured at 
increasing doses of methacholine (0.5-8mg/ml). Surprisingly, no significant 
difference was found following the transfer of either OT-I or IFN-γ
-/-
OT-I CD8 T cells 
compared to OVA-immunized and challenged mice (Fig 5.6). So while airway 
inflammation and mucus secretion are inhibited by OT-I CD8 T cells, there is no 
evidence that these cells, transferred at the elicitation phase, could modify lung 
function. This implies that different mechanisms might be involved in cell infiltration 
and AHR. 














Fig 5.6 Airway hyperresponsiveness in response to CD8 T cell transfer.  Mice 
were immunized on days 0 and 14, adoptively transferred with effector CD8 T cells 
on day 20 and challenged on days 21-23. To assess AHR, mice were heavily 
anesthetized with an anesthesia cocktail of ketamine and medetomidine. Airway 
responsiveness was measured as the change in airway resistance (RI) to increased 
concentration of nebulized methacholine (0.5–8.0 mg/ml). Mice were 
tracheostomized and mechanically ventilized at a fixed breathing rate of 
140breaths/min and the airway resistance (RI) were recorded. Results are expressed 
as percentages of respective basal values in response to PBS. 
++
 p<0.01 (compared 



































































We have shown in this chapter that effector OT-I CD8 T cells successfully attenuated 
eosinophilia and mucus production when transferred at the elicitation phase of OVA-
induced asthma while effector IFN-γ
-/-
OT-I CD8 T cells exacerbate rather than inhibit 
eosinophilia and failed to modulate mucus secretion. There was no evidence that 
effector CD8 T cells were able to modulate airway hyperresponsiveness, IFN-γ-
producing or not. 
 
Consistent with previous findings (Huang et al., 1999; Ishimitsu et al., 2001; Suzuki 
et al., 2002; Suzuki et al., 1999; Takeda et al., 2009a; Wells et al., 2007a), our data 
showed that CD8 T cells were able to attenuate Th2 inflammation and the absence of 
IFN-γ ameliorated CD8 T cell-mediated inhibition of eosinophilia and goblet cell 
hyperplasia. However, previous studies by Miyahara et al. and Taube et al. observed 
increased inflammation, attributing these changes to pro-inflammatory effector 
memory rather than central memory T cells (Miyahara et al., 2004a; Taube et al., 
2006). These findings seemed contradictory to our observation that effector CD8 T 
cells inhibited rather than promoting Th2 inflammation. This conflict could partly be 
explained by the different approaches utilized. In these previous studies, endogenous 
CD8 T cells were depleted during the sensitization phase as opposed to our study in 
which CD8 T cells were transferred to mice in which an endogenous CD8 response 
was already established. Our study therefore focuses more on the ability of CD8 T 




cells to influence an ongoing Th2 inflammation as well as the ability of these cells to 




OT-I CD8 T cells greatly increased eosinophilia and neutrophilia 
resulting in an exaggerated Th2 and Th1 responses. The pro-inflammatory feature of 
these CD8 T cells might be a combined result of their biased production of Tc2/Tc17 
cytokines and reduced cytotoxicity. It is consistent to the detrimental role of Tc2 cells 
in allergic responses as shown in a few previous studies (Sawicka et al., 2004; 
Schaller et al., 2005; Stock et al., 2004a). Tc17 cells have not been extensively 
studied in asthma models thus far although Th17 and the cytokine IL-17 that they 
secret have been described in quite a few studies  (He et al., 2007; McKinley et al., 
2008; Molet et al., 2001; Wakashin et al., 2008; Wilson et al., 2009). The pro-
inflammatory nature of the IFN-γ
-/-
OT-I CD8 T cells will be further discussed in 
Chapter 8. 
 
While the reduction of cell infiltration and mucus production by CD8 T cells was 
evident,  AHR did not seem to be affected. Some previous studies have shown that 
some cardinal features of asthma such as eosinophilic inflammation and airway 
remodeling were also shared by eosinophilic bronchitis while AHR was exclusive to 
asthma (Brightling et al., 2002a; Brightling et al., 2002b; Gibson et al., 1989), 
suggesting that the participation of different factors may contribute to different 
immunopathologic features of asthma (Robinson, 2010). Thus, it is possible that the 
inhibition of AHR might also require the coordination of other factors in concert with 




CD8 T cells. Moreover, although modulating inflammation was found to have an 
effect on AHR, different cell types were involved including eosinophils, neutrophils 
and mast cells and eosinophils were not necessarily the major cell type associated 
with AHR (Berend et al., 2008; Busse, 2010; Gibson et al., 2000). Indeed, the 
relationship between eosinophilils and AHR has been in doubt due to the failure of 
using IL-5 blocking antibody to suppress AHR although it did efficiently reduce 
eosinophilia (Leckie et al., 2000). In our study, neutrophils were increased in response 
to CD8 T cells transfer which may counter the inhibitory effect on AHR by reduced 
eosinophilia.  
 
In contrast to a few previous studies showing that CD8 T cells were able to suppress 
IgE via mechanisms involving IL-12 and IL-18 (Salagianni et al., 2007; Thomas et al., 
2001; Thomas et al., 2002b), the adoptive transfer of CD8 T cells, IFN-γ producing or 
not, failed to modify IgE response in our study. A possible explanation is that opposed 
to those previous studies in which CD8 T cells were introduced rather early in the 
course of sensitization (either right before or one day after the sensitization), the CD8 
T cells in this study were only transferred to immunized mice one day before the 
challenges started. The antibody response was already well established and stabilized 
by then (day20) which left small room for modulation by the transferred cells. 
 
 




CHAPTER 6: Effector OT-I CD8 T cells interact with DCs and condition them 




In chapter 5, we have shown that OT-I CD8 T cells were able to suppress Th2 
inflammation while IFN-γ
-/-
OT-I CD8 T cells were not only unable to attenuate Th2 
inflammation but exacerbated both Th1 and Th2 inflammation. It is thus interesting to 
look into the possible underlying mechanisms by which CD8 T cells regulate 
inflammatory process.  
  




 DCs which are 





DCs that cross-present antigens via MHC I to CD8 T cells (del Rio et al., 2007; Sung 
et al., 2006a). Both subsets of DCs are capable of producing IL-12p70 (D'Andrea et 
al., 1992; Sung et al., 2006a) which favors Th1 differentiation (Hsieh et al., 1993; 
Manetti et al., 1993). The involvement of DCs in the pathogenesis of asthma has long 
been recognized and extensively studied by various groups (de Heer et al., 2004; 
Eisenbarth et al., 2002b; Lambrecht et al., 2000; Lambrecht and Hammad, 2009; 
Lewkowich et al., 2008; Matsubara et al., 2006; Piggott et al., 2005). However, not 
much attention has been paid to the function of different subsets of DCs in the 
regulation of asthma.  




We have previously shown that cognate interaction between CD8 T cells and splenic 
DCs is able to induce substantial DC production of IL-12p70 and thus CD4 T cell 
differentiation in vitro in an IFN-γ-dependent manner (Wong et al., 2008). However, 
we have not looked into the relationship between CD8, CD4 T cells and lung DCs. 
Although lung DCs differ significantly from splenic DCs both in terms of surface 
molecule expression and actual function, there is no evidence that lung DCs could not 
be regulated by CD8 T cells as splenic DCs were shown to be. As lung DCs were 
believed to be more potent in promoting aTh2 environment (Lambrecht et al., 2000; 
Lambrecht and Hammad, 2009) and the transfer of effector OT-I CD8 T cells were 
shown to inhibit Th2 responses, it is highly logical to hypothesize that the transferred 
CD8 T cells might interact with lung DCs and dampen their Th2-promoting capability.   
 
In this chapter, we aim to find a possible link between the CD8 T cells and the 
attenuated Th2 responses. Particularly, we are interested to identify the effect of 
transferred CD8 T cells on the different DC populations in the lung in terms of their 
abundance and functionality.  
 




6.2 Unaffected cell infiltration in the airway following wild type CD8 T cell 
transfer  
We have shown that antigen-specific CD8 T cells (OT-I CD8 T cells) could 
efficiently attenuate OVA-induced eosinophilia when transferred before OVA 
challenge. However, it is unclear whether the inhibitory effect of CD8 T cells is 
purely dependent on the cytokines produced by the transferred CD8 T cells or 
dependent on antigen-specificity and potential interaction between the transferred 
CD8 T cells and the endogenous environment. To verify the necessity of antigen 
specificity, non antigen-specific CD8 T cells isolated from wild type mice were used 
to compare with OT-I CD8 T cells. To enable tracking of the transferred cells, wild 
type mice with CD45.1 background was used instead of the commonly used CD45.2 
mice and recruited cells could be identified by CD45.1 staining.  
 
Wild type and OT-I CD8 T cells were stimulated in vitro with PMA and ionomycin 
before adoptive transfer. The percentage of non antigen-specific CD8 T cells in the 
lung (10%) which were stained positive for CD45.1 was about one third of that of the 
antigen-specific ones which were represented by positive H-2K
b
/SIINFEKL tetramer 
staining (30%) (Fig 6.2.1). This could be due to less efficient recruitment of wild type 
CD8 T cells or slower proliferation of these cells in vivo due to the lack of appropriate 
interaction or a combination of both.  
 




To assess whether the infiltration of cells in the airway was modified by the transfer 
of wild type CD8 T cells, BAL fluid was collected and the cells were again stained 
with Siglec-F, CD11c, Ly-6G and CD3. While OT-I CD8 T cells were again able to 
inhibit the infiltration of eosinophils, wild type CD8 T cells failed to do so (Fig 6.2.2), 
suggesting that without antigen-specificity, effector CD8 T cells were not capable of 
suppressing Th2 inflammation.   
 
Together, these data suggest that unlike OT-I CD8 T cells, wild type CD8 T cells are 
not able to modulate eosinophilia, indicating that to exert the modulatory effect, 









Fig 6.2.1 Recruitment of non antigen-specific CD8 T cells into the lung.  Mice 
were immunized on days 0 and 14, adoptively transferred with effector CD8 T cells 
on day 20 and challenged on days 21-23. Lung tissues were collected one day 24 and 
stained with CD45.1 or SIINFEKL. (A) Percentage of CD45.1
+
CD8 T cells in the 
lung. (B) Percentage of SIINFEKL
+
CD8 T cells in the lung. 
++
 p<0.01 (compared 




 p<0.01 (compared with PBS/PBS group); 
***
 



















































































































































Fig 6.2.2 Infiltration of granulocytes in response to non antigen-specific CD8 T 
cell transfer.  Mice were immunized on days 0 and 14, adoptively transferred with 
effector CD8 T cells on day 20 and challenged on days 21-23. BAL fluid was 
collected one day after the last challenge and stained with Siglec-F, CD11c, Ly-6G 
and CD3. Summarized result and statistical analysis for the infiltrated eosinophils, 
neutrophils, macrophages and T lymphocytes were shown. 
+
 p<0.05 (compared with 
PBS/PBS group); 
*
 p<0.05 (compared with PBS/PBS group). (n=3). (One-way 




















































6.3 Increased antigen presenting cells in the lung in response to CD8 T cell 
transfer 
Dendritic cells have long been recognized as a very important player in the 
pathogenesis of asthma and we have previously shown that CD8 T cells could interact 
with DCs and induce them to prime CD4 T cells. Hence, to determine whether the 
transferred CD8 T cells could affect the DC population in the lung and their function, 
lung parenchymal cells were enriched using opti-prep density centrifugation and 









 DCs. In control mice, all types of APCs 








 DCs were quite comparable (Fig 6.3). With OVA immunization and 









 DCs remained unchanged (Fig 6.3). Following the 
adoptive transfer of both OT-I and IFN-γ
-/-









 DCs were increased largely compared to 





DCs became the dominant APCs in these mice. No significant 
difference was found for macrophages in all the groups of mice (Fig 6.3). These data 
suggest that following the transfer of antigen-specific CD8 T cells, DC numbers in 




DCs are the dominant DC subtype.  














Fig 6.3 Antigen presenting cells in response to CD8 T cell transfer.  Mice were 
immunized on days 0 and 14, adoptively transferred with effector CD8 T cells on day 
20 and challenged on days 21-23. Lung tissues were collected one day after the last 
challenge and stained with CD11c, MHCII, CD11b and CD103. Summarized result 








 DCs in the lung were shown. 
+ 
p<0.05 (compared with PBS/PBS group); 
*
 
p<0.05 (compared with PBS/PBS group); 
**
 p<0.01. (n=5). (One-way ANOVA with 

































































 DCs from the lung 
Now that we have identified the up-regulated DC populations in the lung following 
CD8 T cells transfer, we would like to examine the function of these DCs. To purify 
different DC subsets, stained cells were subjected to cell sorting using MoFlo. Cells 
with high pulse width which were usually the doublets or even clumps with multiple 
cells were excluded to make sure the cells we eventually collected were single cells 
(Fig 6.4A upper panel, left). These singlet cells were then further selected for those 
with low to medium granularity reflected by the side scatter reading (Fig 6.4A upper 




 cells were gated on  (Fig 6.4A upper 






















 DCs in the lung. Purities of the sorted cells were 









 DCs (>92%) (Fig 6.2.3B).  



















































































 DCs from the lung. 
Mice were immunized on days 0 and 14, adoptively transferred with effector CD8 T 
cells on day 20 and challenged on days 21-23. Lung tissues were collected one day 
after the last challenge. Lung tissues were first digested with liberase for 45 minutes 
at 37°C and then  pressed through cell strainer to obtain single cell suspension. After 
opti-prep enrichment, cells were stained for CD11c, MHCII, CD11b and CD103. 
Labeled cells were then subjected to sorting using MoFlo. (A) Gating strategy for DC 




 area which was then 

















 DCs.  




6.5 Conditioning of naïve CD4 T cells by lung DCs in response to CD8 T cell 
transfer 
Since the numbers of DCs in the lung increased in response to CD8 T cell transfer, 
the next step would be functional study to find out whether these DCs were modified 
in their CD4 priming capability. One day after the last challenge, lung parenchymal 









 DCs were collected and used as antigen presenting cells in our co-
culture system. To obtain naive antigen-specific CD4 T cells, CD4 T cells purified 




 naive cells (Fig 6.5.1A). A 
similar gating strategy was used to obtain the singlet cells with low granularity as 
shown for the purification of DC subsets. To exclude auto-fluorescent cells, CD4
+
 




 cells were 
collected. Purity of the naïve CD4 T cells were regularly examined and it remained 
high (>95%) (Fig 6.5.1B). These naive CD4 T cells were then co-cultured with DCs 
from different groups of mice at 10:1 ratio in the presence of OVA for four days. The 





 DCs from the mice with OT-I CD8 T cell transfer induced high 
amount of IFN-γ production by naive CD4 T cells while DCs from mice transferred 
with IFN-γ
-/-
OT-I CD8 T cells were not able to enhance IFN-γ production by CD4 T 





 DCs from mice with CD8 T cell transfer failed to 









and no significant difference was found among groups (Fig 6.5.2B). These data 
suggest that the transfer of OT-I CD8 T cells condition lung parenchymal DCs for 
CD4 T cell priming to Th1 and it is dependent on CD8 IFN-γ.  This could be one of 
the mechanisms by which CD8 T cells inhibit Th2 responses. 
 






















Fig 6.5.1 Purification of naïve CD4 T cells from OT-II mice. Spleens and lymph 
nodes of OT-II mice were harvested and CD4 T cells were obtained using positive 
magnetic selection. These cells were stained with CD4, CD62L and CD44 and 































































Naïve CD4 T cells
















Fig 6.5.2 Priming of naïve CD4 T cells by DCs in response to CD8 T cell transfer.  
Mice were immunized on days 0 and 14, adoptively transferred with effector CD8 T 
cells on day 20 and challenged on days 21-23. Lung tissues were collected one day 








 DCs were sorted and 







4 days in the presence of 100µg/ml OVA. IFN-γ production in the supernatant was 











 p<0.01 (compared with OVA/OVA group or as indicated on the 














































































6.6 Conditioning of antigen-experienced lung CD4 T cells by DCs in response to 
CD8 T cell transfer 
In OVA immunized mice, the DCs conditioned by the transferred CD8 T cells would 
have more chances of interacting with antigen-experienced CD4 T cells than naive 
CD4 T cells. We wanted to figure out whether DCs from CD8 T cell transferred mice 
could also skew the cytokine production profile of the lung CD4 T cells. DCs were 








 DCs and co-cultured with 
CD4 T cells isolated from the respectively treated mice at a 1:10 ratio in the presence 
of OVA for four days. Supernatant was harvested and IFN-γ level was measured by 
ELISA. Similar to the naïve CD4 T cells, lung parenchymal CD4 T cells from OT-I 










 DCs from control and OVA immunized and challenged 
mice did not yield any significant IFN-γ production (Fig 6.6A).  Although IFN-γ 





 DCs from mice with IFN-γ
-/-
OT-I CD8 T cell transfer, the level was 
much lower than in the co-culture from mice with OT-I CD8 T cell transfer (Fig 




 DCs, the overall concentration of IFN-γ detected in the 




 DCs (Fig 
6.6). Although an increasing trend in the production of IFN-γ could be observed when 
the mice were transferred with CD8 T cells, no significant difference could be found 
(Fig 6.6B). These data suggest that not only could the CD8-conditioned DCs skew the 




differentiation of naïve CD4 T cells; they could also enhance the production of Th1 
cytokine IFN-γ from antigen-experienced lung CD4 T cells in a CD8 IFN-γ-











Fig 6.6 Conditioning of lung CD4 T cells by DCs in response to CD8 T cell 
transfer.  Mice were immunized on days 0 and 14, adoptively transferred with 
effector CD8 T cells on day 20 and challenged on days 21-23. Lung tissues were 








 DCs were sorted and 
cultured with antigen-experienced lung CD4 T cells isolated from respective group of 
mice for 4 days in the presence of 100µg/ml OVA. IFN-γ production in the 












 p<0.001 (compared with OVA/OVA group or as indicated 



















































































In this chapter, we have shown that effector CD8 T cells modulate Th2 inflammation 
in an antigen-specific manner which led us to examine the function of lung 
parenchymal DCs after the possible interaction between them and CD8 T cells.  




 DC population 





 DCs from mice with OT-I CD8 T cell transfer had increased Th1 
priming capacity and were able to potentiate IFN-γ production while those from IFN-
γ
-/-
OT-I CD8 T cell transfer recipient mice were much less effective at inducing or 
potentiating IFN-γ production, suggesting that the interaction between the transferred 





 DCs  could be one mechanism via which CD8 T cells modify Th2 
responses in our model of asthma. 
 
Transfer of exogenous CD8 T cells has been adopted by various research groups to 
study the role of CD8 T cells in asthma, partly due to the presence of rather limited 
number of antigen-specific CD8 T cells in asthma models. Rarely in those previous 
studies, was antigen specificity of the transferred cells discussed in much detail 
although antigen-specific transgenic CD8 T cells were usually used instead of wild 
type CD8 T cells. In our study, we compared the modulating effect of OT-I CD8 T 
cells with CD8 T cells from wild type mice and found that not only was the 
percentage of recruited wild type CD8 T cells and their daughter cells much lower 




than the antigen-specific CD8 T cells, these wild type CD8 T cells did not attenuate 
eosinophilia, suggesting that the inhibitory effect of effector CD8 T cells was 
dependent on antigen specificity. Notably, although the percentage of CD45.1
+
 CD8 T 
cells in mice with wild type CD8 T cell transfer was much lower than the SIINFEKL
+
 
CD8 T cells in those with OT-I CD8 T cell transfer, it is dangerous to conclude that 
the recruitment of wild type CD8 T cells was less efficient. As the transferred OT-I 
CD8 T cells continued to proliferate as we have shown in chapter 4 and wild type 
CD8 T cells might proliferate at a slower rate due to the lack of antigen specificity, it 
might be a combination of the difference in recruitment as well as in proliferation that 
contributed to the striking gap in the different percentages of CD8 T cells in the lung.  
 
The fact that antigen specificity was required indicated that IFN-γ was not the only 
factor that contributed to the inhibitory effect of CD8 T cells and DCs as the major 
APCs in the lung were the most attractive candidate in our search for the underlying 
mechanisms. Although studies have shown that either endogenous lung DCs (de Heer 
et al., 2004; Eisenbarth et al., 2002b; Lambrecht and Hammad, 2009; Lewkowich et 
al., 2008; Thomas et al., 2002a; van Rijt et al., 2005) or bone marrow derived DCs 
(Lambrecht et al., 2000; Matsubara et al., 2006; Piggott et al., 2005) were sufficient in 
inducing Th2 responses to allergens, not much detail was revealed on the role of 















predominates in OVA-induced inflammation. As the transfer of effector CD8 T cells 








DCs independent of IFN-γ, it was thus important 
to find out whether these DCs were functionally modified.  Interestingly, these 
supposedly type II biased DCs became potent inducers of IFN-γ after the possible 
interaction with the transferred OT-I CD8 T cells. This finding correlated well with 
our previous study that interaction with activated CD8 T cells could induce DCs to 
produce IL-12p70 and prime Th1 differentiation (Wong et al., 2008). However, DCs 
from IFN-γ
-/-
OT-I CD8 T cell transfer recipient mice were not able to induce IFN-γ 
production as efficiently. One possible explanation was that since the IFN-γ
-/-
OT-I 
CD8 T cells were more Tc2/Tc17-like and produced lots of IL-13 and IL-17, 
interaction with these T cells might not be the right stimulus for the DCs to switch 










 DCs are much less abundant in 
the lungs of immunized and challenged mice either with or without CD8 T cell 
transfer. These cells were also weaker inducers of IFN-γ production probably due to 
their less efficient antigen presentation via the MHC II pathway as they were shown 
to be more effective in cross presentation via MHC I pathway to CD8 T cells (del Rio 




 DCs are not entirely 



























 DCs were shown 
to play an essential role in Th2 differentiation in vivo (Nakano et al., 2011). This 
difference in CD4 T cell priming provided another possible explanation for the low 






These findings indicate that the combination of IFN-γ production and a Tc1 
phenotype is essential to alter DC cell function, favoring CD4 T cell differentiation to 
the Th1 phenotype even within a predominantly Th2 lung and demonstrate a novel 
potential mechanism through which CD8 T cells attenuate eosinophilia.   




CHAPTER 7: IFN-γ neutralization restores allergic inflammation inhibited by 
OT-I CD8 T cells 
 
7.1 Introduction 
The comparison between the phenotypes of effector OT-I and IFN-γ
-/-
OT-I CD8 T 
cells showed that IFN-γ
-/-
OT-I CD8 T cells did not only differ from OT-I CD8 T cells 
in their ability to produce IFN-γ, but differed from the IFN-γ-producing CD8 T cells 
in other aspects. Silencing the IFN-γ gene led to a number of intrinsic changes which 
made the activated IFN-γ
-/-
OT-I CD8 T cells poorer killers but more potent producers 
of IL-13 and IL-17 compared to their IFN-γ-producing counterparts. It is unclear 
whether the absence of Th2 inhibition and promotion of inflammation by IFN-γ
-/-
OT-
I CD8 T cells was simply due to their lack of IFN-γ or rather because of the altered 
properties of these cells. It is likely that the effect of IFN-γ
-/-
OT-I CD8 T cells was the 
result of a combination of multiple factors.  
 
In the literature, a lot of studies focusing on the role of IFN-γ adopted IFN-
γ neutralizing antibody to block the activity of IFN-γ as we mentioned in previous 
chapters (Isogai et al., 2007; Polte et al., 2007; Takeda et al., 2009a). If IFN-γ is 
neutralized in vivo right before or after cell transfer, the intrinsic properties of the 
transferred cells would not be altered as those cells were still the IFN-γ-producing 
cells. Thus, in this chapter, we also employed IFN-γ neutralizing antibody to dissect 




the contribution of IFN-γ from that of the altered intrinsic properties of the CD8 T 
cells. However, cytokine neutralization with antibody is not a cell-specific system and 
that wherever the antibody reaches, IFN-γ at that site will be neutralized. To minimize 
the systemic effects, anti-IFN-γ antibody was given locally via intra-tracheal route 
and right before the transfer of the cells. Similarly, cell infiltration, mucus production 
and lung DC function were examined to identify the role of IFN-γ in the modulating 
effect of CD8 T cells. A preliminary study using IFN-γR
-/-
 mice was also conducted 
to further verify the effect of IFN-γ on the inhibitory role of CD8 T cells. 
 




7.2 Eosinophil and neutrophil infiltration into the airways in response to CD8 T 
cell transfer and IFN-γ neutralization 
Other than the difference in IFN-γ production, IFN-γ
-/-
OT-I CD8 T cells still differ 
significantly from OT-I CD8 T cells in various aspects: IL-13 and IL-17 production, 
transcription factor expression and cytotoxic activity. To solely focus on the role of 
IFN-γ, we adopted IFN-γ-neutralizing antibody. 300µg of anti-IFN-γ antibody was 
given to mice via intra-tracheal route right before the adoptive transfer of OT-I CD8 
T cells. BAL fluid cells were collected and stained with Siglec-F, CD11c, Ly-6G and 
CD3. Consistently, eosinophil infiltration was profound in OVA immunized and 
challenged mice (Fig 7.2).  Upon the transfer of OT-I CD8 T cells, the number of 
eosinophils in the BAL fluid was significantly reduced while the numbers of 
neutrophils and T lymphocytes were increased (Fig 7.2). When anti-IFN-γ antibody 
was given, the reduction in eosinophilia induced by the transfer of CD8 T cells was 
compromised with the infiltration of neutrophils and T lymphocytes unaffected (Fig 
7.2).  Interestingly, neutralization of IFN-γ merely restored the level of eosinophil 
infiltration when compared to the OVA immunized and challenged mice, but did not 
potentiate inflammation as the IFN-γ
-/-
OT-I CD8 T cells did (Fig 5.4). This finding 
indicates that not only is the production of IFN-γ per se responsible for the 
modulation of inflammation by CD8 T cells, but that other factors might also be 
involved. The study with IFN-γ
-/-
OT-I CD8 T cells implies that without the ability to 
produce IFN-γ, CD8 T cells are intrinsically changed which might be responsible for 




the enhancement of inflammation when these cells are transferred to OVA-
immunized mice.   
 
Together, these data suggest that the inhibitory effect of effector OT-I CD8 T cells on 
the infiltration of eosinophils is IFN-γ-dependent and is confirmed by the 
neutralization of IFN-γ. However, the potentiation of inflammation is not due to the 
simple deficiency in IFN-γ but rather the intrinsic changes in the CD8 T cells when 
they are deficient in IFN-γ production. 
 















Fig 7.2 Infiltration of granulocytes in the BAL in response to CD8 T cell transfer 
and IFN-γ neutralization.  Mice were immunized on days 0 and 14, adoptively 
transferred with effector CD8 T cells on day 20 and challenged on days 21-23. IFN-γ 
neutralizing antibody was given to mice right before the transfer of CD8 T cells. BAL 
fluid was collected one day after the last challenge. BAL cells were stained with 
Siglec-F, CD11c, Ly-6G and CD3 and analyzed by flow cytometry. Summarized 
results and statistical analysis for the numbers of macrophages, eosinophils, 
neutrophils and T lymphocytes in the BAL are shown. 
+++
 p<0.001 (compared with 
PBS/PBS group); 
*
 p<0.05 (compared with OVA/OVA group);
 **
 p<0.01. (n=3). 


















































7.3 Mucus secretion in the lung in response to CD8 T cell transfer and IFN-γ 
neutralization 
To evaluate whether blocking IFN-γ could neutralize the inhibitory effect of CD8 T 
cells on mucus production, perfused and fixed lungs were dehydrated and sectioned 
to 4µm and stained with periodic acid and schiff’s reagent. Mucus-producing goblet 
cells were identified as the pink staining lining inside the epithelial cells. OVA 
immunization and challenge induced large amount of mucus producing cells which 
was significantly attenuated by the transfer of OT-I CD8 T cells (Fig 7.3). IFN-γ 
neutralization successfully restored the level of mucus production which was 
comparable to OVA immunized and challenged mice (Fig 7.3). Airway thickening 
could be observed in all the groups expect for the PBS control (Fig 7.3). These data 
suggest that the transfer of OT-I CD8 T cells successfully alleviates mucus 
production in an IFN-γ-dependent manner. 

























Fig 7.3 Mucus production in response to CD8 T cell transfer and IFN-γ 




























































effector CD8 T cells on day 20 and challenged on days 21-23. IFN-γ neutralization 
antibody was given to mice right before the transfer of CD8 T cells. Mice were 
sacrificed one day after the last challenge. Fixed lungs were dehydrated and 
embedded in paraffin, sectioned to 4µm and stained with periodic acid. (A) 
Representative histological images were shown for different treatment groups at 10 
and 40× magnifications. (B) Scored analysis of PAS-positive areas. 
+++
 p<0.001 
(compared with PBS/PBS group); 
***
 p<0.001 (compared with OVA/OVA group). 
(n=3). (One-way ANOVA with Tukey’s Multiple Comparison Test). 




7.4 Conditioning of naïve CD4 T cells by lung DCs in response to CD8 T cell 
transfer and IFN-γ neutralization 
To study whether IFN-γ neutralization would affect the conditioning of DCs by CD8 
T cells, a DC-CD4 T cell co-culture system was utilized. One day after the last 









 DCs were collected and used in DC-




 naive CD4 T cells were obtained from OT-II 
mice by cell sorting. These naive CD4 T cells were co-cultured with DCs from 
different groups of mice at 10:1 ratio in the presence of OVA for four days. IFN-




 DCs from mice 
that received OT-I CD8 T cells induced high amounts of IFN-γ production from naive 
CD4 T cells while DCs from mice transferred with OT-I CD8 T cells and IFN-
γ neutralizing antibody induced lower levels of IFN-γ production from CD4 T cells 
which was not significant when compared to OVA immunized and challenged mice 




 DCs from mice with CD8 T cell transfer failed to 
induce IFN-γ production from the CD4 T cells and no significant difference was 
found among groups (Fig 7.4B). Together, these data suggest that the transfer of OT-I 




DCs for CD4 T cell priming 
to Th1 and the neutralization of IFN-γ would inhibit that capacity.   















Fig 7.4 Priming of naïve CD4 T cells by DCs in response to CD8 T cell transfer 
and IFN-γ neutralization.  Mice were immunized on days 0 and 14, adoptively 
transferred with effector CD8 T cells on day 20 and challenged on days 21-23. IFN-γ 
neutralization antibody was given to mice right before the transfer of CD8 T cells. 









 DCs were sorted and cultured with freshly-isolated and sorted naïve 






) for 4 days in the presence of 100µg/ml OVA. 
IFN-γ production in the supernatant was determined by ELISA. (A) IFN-γ proudtion 




 DCs. (B) IFN-γ proudtion by CD4 T 






 p<0.05 (compared with OVA/OVA group). 












































































7.5 Conditioning of antigen-experienced lung CD4 T cells by DCs in response to 
CD8 T cell transfer and IFN-γ neutralization 
We have argued in Chapter 6 that lung DCs in OVA immunized mice were more 
likely to interact with antigen-experienced CD4 T cells rather than naïve CD4 T cells. 









 DCs sorted from the respectively treated 
mice at a 10:1 ratio in the presence of OVA for four days. The supernatant was 
harvested and IFN-γ level was measured by ELISA. Similar to the naïve CD4 T cells, 




DC-CD4 T cells from the mice with OT-I CD8 T 
cell transfer yielded large amounts of IFN-γ which was attenuated if the cells were 




 DCs, although an increasing trend in the production of IFN-γ could be 
observed when the mice were transferred with CD8 T cells, no significant difference 
could be found (Fig 7.5B). These data suggest that CD8 T cells could condition DCs 
to enhance the production of IFN-γ by lung CD4 T cells in a CD8 IFN-γ-dependent 
manner.  















Fig 7.5 Conditioning of lung CD4 T cells by DCs in response to CD8 T cell 
transfer and IFN-γ neutralization.  Mice were immunized on days 0 and 14, 
adoptively transferred with effector CD8 T cells on day 20 and challenged on days 
21-23. IFN-γ neutralization antibody was given to mice right before the transfer of 









 DCs were sorted and cultured with antigen-
experienced lung CD4 T cells isolated from respective group of mice for 4 days in the 
presence of 100µg/ml OVA. IFN-γ production in the supernatant was determined by 
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As IFN-γ is produced in large amounts and by various cell types, although 
neutralizing antibody could temporarily block IFN-γ, the effect is not long lasting. To 
further confirm the role of IFN-γ in the inhibitory effect of CD8 T cells, we employed 
IFN-γR
-/-
 mice. These mice do not respond to IFN-γ as the cells do not express IFN-γ 
receptor. Interestingly, OVA immunization and challenges induced more severe 
eosinophilia in these knock out mice (Fig 7.6) when compared to wild type mice (Fig 
3.4.2B & Fig 5.4.1B) and no significant neutrophilia was induced (Fig 7.6). OT-I 
CD8 T cells were not able to inhibit eosinophil infiltration in these mice and induced 
a slight increase in BAL neutrophils and lymphocytes (Fig 7.6). These data suggest 
that in the absence of IFN-γ signaling, CD8 T cells are not able to exert their 
suppressive role on Th2 inflammation which is consistent to the findings using IFN-γ
-
/-
OT-I mice or neutralization antibody.   
 
 














Fig 7.6 Infiltration of granulocytes in the BAL in response to CD8 T cell transfer 
in IFN-γR
-/-
 mice.  Mice were immunized on days 0 and 14, adoptively transferred 
with effector CD8 T cells on day 20 and challenged on days 21-23. BAL fluid was 
collected one day after the last challenge. BAL cells were stained with Siglec-F, 
CD11c, Ly-6G and CD3 and analyzed by flow cytometry. Summarized results and 
statistical analysis for the numbers of macrophages, eosinophils, neutrophils and T 
lymphocytes in the BAL were shown. 
++
 p<0.01 (compared with PBS/PBS group); 
*
 
p<0.05 (compared with OVA/OVA group). (n=3). (One-way ANOVA with Tukey’s 
Multiple Comparison Test). 










































We have shown in this chapter that in vivo IFN-γ neutralization compromised the 





DCs in mice administered with IFN-γ neutralizing antibody immediately before the 
transfer of effector OT-I CD8 T cells were less effective at inducing IFN-γ production 
by both naive and antigen-experienced CD4 T cells. However, in contrast to mice 
transferred with IFN-γ
-/-
OT-I CD8 T cells, neutralization of IFN-γ did not potentiate 
Th1 or Th2 inflammation, but merely restored the level of inflammation to that in 
OVA immunized and challenged mice. Similarly, in IFN-γR
-/-
 mice, OT-I CD8 T 
cells failed to suppress eosinophilia, further emphasizing the importance of IFN-γ in 
the inhibitory effect of CD8 T cells.  
 
The approach using anti-IFN-γ neutralizing antibody enables us to specifically focus 
on the contribution of IFN-γ in the regulatory role of CD8 T cells. However, the 
efficiency of neutralization can be compromised by the continuous production of 
endogenous IFN-γ. Indeed, even with 300µg neutralizing antibody, the BAL fluid still 
had significant levels of IFN-γ on the day of sacrifice (data not shown). While the 
effect of blocking might not be complete and rendered the conclusion of IFN-γ-
dependent suppression a bit weak, the lack of suppression by CD8 T cells in IFN-γR
-/-
 
mice somewhat strengthened the hypothesis that IFN-γ signaling was crucial. 
Interestingly, the inflammation induced by OVA immunization and challenge in IFN-
γR
-/-
 mice was more profound than in wild type mice. Although the same batch of 




OVA with same amount of endotoxin contamination was used, it seemed that no 
significant neutrophilia was induced. A possible explanation is that since IFN-γR
-/-
 
mice do not respond to IFN-γ, they are naturally biased towards a type II response. 
Nevertheless, the fact that OT-I CD8 T cells are not able to suppress eosinophilia in 
these mice highlights the dependence on IFN-γ signaling. Indeed, in IFN-γ
-/-
 mice, 
OVA-induced eosinophilia was also more severe than in wild type mice, probably 
due to skewed Th2 response similar to IFN-γR
-/-
 mice. However, in IFN-γ
-/-
 mice, 
OT-I CD8 T cells were able to suppress eosinophilia as shown in wild type mice (data 
not shown). This finding implies that even when a stronger Th2 response is induced, 
CD8 T cells are still able to counter it as long as there is intact IFN-γ−IFN-γR 
interaction.  




CHAPTER 8: Effector IFN-γ
-/-
OT-I CD8 T cells induce an asthma-like pathology 




We have shown in previous chapters that in OVA sensitized mice, the transfer of OT-
I CD8 T cells prior to OVA challenge inhibited eosinophilia, while the transfer of 
IFN-γ
-/-
OT-I CD8 T cells induced more severe eosinophilia and neutrophilia. Using in 
vivo IFN-γ neutralization with anti-IFN-γ antibody, we have identified that the 
presence of IFN-γ is crucial for the inhibitory effect of CD8 T cells. However, the 
neutralization of IFN-γ in vivo did not result in the promotion of eosinophilia as 
shown in mice with IFN-γ
-/-
OT-I CD8 T cell transfer. Thus, other aspects rather than 
the deficiency in IFN-γ must be responsible for the enhanced eosinophil infiltration 
induced by IFN-γ
-/-
OT-I CD8 T cells. Since IFN-γ
-/-
OT-I CD8 T cells differ 
significantly from OT-I CD8 T cells in lots of aspects other than the deficiency in 
IFN-γ including: the expression of transcription factors, the production of IL-13 and 
IL-17 and their cytotoxic activities, we were interested to find out whether these cells 
were not only different from OT-I CD8 T cells at a regulatory level, but also 
functionally distinct from OT-I CD8 T cells at the induction phase of the response. To 
achieve this, effector OT-I and IFN-γ
-/-
OT-I CD8 T cells were transferred into naive 
mice followed by OVA challenge so that we could study how these two different 
types of cells could induce cell infiltration differently. 




8.2 Enhanced eosinophil and neutrophil infiltration in the airway in response to 
IFN-γ
-/-
OT-I CD8 T cell transfer and OVA challenge 
To investigate how effector IFN-γ
-/-
OT-I CD8 T cells differ in their ability to induce 
rather than to regulate cell infiltration from effector OT-I CD8 T cells, 3 × 10
6
 of each 
type of cells were transferred into naive mice without any prior exposure to OVA, 
following which, 3 consecutive intranasal challenges were given (Fig 8.1). BAL fluid 
and lung tissues were collected one day after the last challenge. We have shown in 
Chapter 5 that in OVA-immunized mice, the recruitment of both types of cells was 
similar. However, in naive mice, IFN-γ
-/-
OT-I CD8 T cells appeared to be recruited 
more efficiently than OT-I CD8 T cells (Fig 8.2A). Interestingly, these IFN-γ
-/-
OT-I 
CD8 T cells induced profound eosinophilia and neutrophilia while OT-I CD8 T cells 
failed to induce any significant infiltration (Fig 8.2B). A lot of infiltrated T cells 
could also be found in the BAL fluid of mice with IFN-γ
-/-
OT-I CD8 but not OT-I 
CD8 T cell transfer (Fig 8.2B). These data suggest that effector IFN-γ
-/-
OT-I CD8 T 
cells are intrinsically changed and are able to induce inflammation in naive mice 
following allergen challenge while the Tc1-biased effector OT-I CD8 T cells failed to 



















Fig 8.1 Transfer and challenge protocol. C57BL/6 mice were transferred with OT-I 
or IFN-γ
-/-
OT-I CD8 T cells on day 1 followed by 3 consecutive intranasal challenges 
with 100µg OVA starting from day 2. For control mice, intranasal challenge with in 
PBS was given instead. Mice were sacrificed 24 hours after the last challenge. 
0 1  2   3 4
OT-I/IFN-γ-/-OT-I  CD8 i.v OVA i.n Analysis



















Fig 8.2 Recruitment of CD8 T cells and infiltration of granulocytes in response to 
CD8 T cell transfer and OVA challenges. Naive mice were adoptively transferred 
with 3 × 10
6
 OT-I or IFN-γ
-/-
OT-I CD8 T cells on day 0 and followed by 3 
consecutive OVA challenges on days 1-3. Mice were sacrificed on day 4. BAL fluid 
and lung tissues were collected. (A) Percentage of SIINFEKL
+
 CD8 T cells in the 
lung. (B) Infiltration of eosinophils, neutrophils and T lymphocytes into the BAL. 
+
 




 p<0.05 (Compared to PBS/OT-
I/OVA mice); 
**
















































































































8.3 Cell infiltration in the airway in response to different numbers of OT-I CD8 
T cell transfer and OVA challenges 
As the recruitment of effector IFN-γ
-/-
OT-I CD8 T cells was more efficient than OT-I 
CD8 T cells, it then raised the concern that the induced infiltration of eosinophils and 
neutrophils by IFN-γ
-/-
OT-I CD8 T cells might be biased because of the more readily 
available CD8 T cells in the local environment. OT-I CD8 T cells may also be able to 
achieve the same effect if we could get more OT-I CD8 T cells recruited. Thus, to 
enhance recruitment, we increased the number of CD8 T cells for transfer, from 3 × 
10
6
 to 6 × 10
6
. The recruitment of these cells into the lung did not seem to be 
increased significantly even when 6 × 10
6
 cells were transferred (Fig 8.3A). 
Infiltration of eosinophils and neutrophils was not induced by the transfer of 
increasing number of OT-I CD8 T cells either (Fig 8.3B).  The numbers of 
eosinophils and neutrophils remained minimal in the BAL fluid despite the transfer of 
large number of effector OT-I CD8 T cells (below 40,000 when compared to the 
number of eosinophils and neutrophils in mice with effector IFN-γ
-/-
OT-I CD8 T cell 
transfer which reached 200, 000 and 100,000). These data suggest that effector IFN-γ
-
/-
OT-I CD8 T cells are intrinsically more inflammatory than OT-I CD8 T cells which 
enable them to induce robust cell infiltration while OT-I CD8 T cells do not have this 
property and even transferring large number of these cells cannot achieve the same 
effect.   
 



















Fig 8.3 Recruitment of CD8 T cells and infiltration of granulocytes in response to 
the transfer of increasing number of CD8 T cells and OVA challenge. Naive mice 
were adoptively transferred with 3 × 10
6
, 4.5 × 10
6
 or 6 × 10
6
 OT-I CD8 T cells on 
day 0 and followed by 3 consecutive OVA challenges on days 1-3. Mice were 
sacrificed on day 4. BAL fluid and lung tissues were collected. (A) Percentage of 
SIINFEKL
+
 CD8 T cells in the lung. (B) Infiltration of eosinophils, neutrophils and T 




 p<0.001 (Compared to PBS/PBS mice). (n=3). 
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8.4 Cell infiltration in the airway in response to IFN-γ neutralization following 
OT-I CD8 T cell transfer and OVA challenge 
We have shown that effector IFN-γ
-/-
OT-I CD8 T cells but not OT-I CD8 T cells were 
able to induce severe eosinophilia and neutrophilia and that increasing the number of 
OT-I CD8 T cells for transfer was not able to trigger the infiltration either. In this 
section, to further establish that the inflammatory nature of effector IFN-γ
-/-
OT-I CD8 
T cells was more dependent on the intrinsic changes induced due to the lack of IFN-γ 
rather than the absence of IFN-γ per se, IFN-γ neutralizing antibody was given to 
mice prior to effector OT-I CD8 T cell transfer. The neutralization of IFN-γ did not 
affect the recruitment of the transferred CD8 T cells (Fig 8.4A).  As expected, IFN-γ 
neutralization did not enable the Tc1-biased effector OT-I CD8 T cells to induce cell 
infiltration as no significant difference was observed between the mice with effector 
OT-I CD8 T cell transfer and those with IFN-γ neutralization prior to cell transfer 
(Fig 8.4B). These data suggest that the inflammatory nature of effector IFN-γ
-/-
OT-I 
CD8 T cells is not the direct result of IFN-γ deficiency, but rather the result of the 
changed cytokine production profile (IL-13 and IL-17) and maybe also the result of 
the changed cytotoxicity since simple neutralization of IFN-γ does not enable the 
effector OT-I CD8 T cells to induce cell infiltration. 



















Fig 8.4 Recruitment of CD8 T cells and infiltration of granulocytes in response to 
OT-I CD8 T cell transfer and IFN-γ neutralization. Naive mice were adoptively 
transferred with 3 × 10
6
 OT-I CD8 T cells and intra-tracheally inoculated with 300µg 
anti-IFN-γ antibody on day 0 and followed by 3 consecutive OVA challenges on days 
1-3. Mice were sacrificed on day 4. BAL fluid and lung tissues were collected. (A) 
Percentage of SIINFEKL
+
 CD8 T cells in the lung. (B) Infiltration of eosinophils, 




 p<0.01 (Compared to 































































































In this chapter we have demonstrated that IFN-γ
-/-
OT-I CD8 T cells were recruited 
into the lung of naive mice more efficiently than OT-I CD8 T cells upon OVA 
challenge. Transfer of IFN-γ
-/-
OT-I CD8 T cells followed by OVA challenge resulted 
in an asthma-like pathology that included both eosinophilia and neutrophilia in non-
immunized mice while OT-I CD8 T cells failed to do so. In vivo neutralization of 
IFN-γ in OT-I CD8 T cell transfer recipient mice did not trigger the induction of 
inflammation, nor did increasing the number of OT-I CD8 T cells. These findings 
suggest that the pro-inflammatory feature of effector IFN-γ
-/-
OT-I CD8 T cells is an 
intrinsic property which effector OT-I CD8 T cells do not possess.   
 
The recruitment of OT-I and IFN-γ
-/-
OT-I CD8 T cells was different although the 
same numbers of cells were transferred. As cell migration and recruitment is highly 
dependent on adhesion molecules and chemotactic factors, a possible explanation is 
that Tc1-biased OT-I CD8 T cells and Tc2/Tc17-oriented IFN-γ
-/-
OT-I CD8 T cells 
may have different adhesion molecules and chemokine receptors. As shown in a few 
previous studies on CD4 and CD8 T cell subsets (Sasaki et al., 2008; Sinigaglia and 
D'Ambrosio, 2000) as well as on different status of CD8 T cells such as naive vs 
effector (Nolz et al., 2011b),  expression of adhesion molecules and chemokine 
receptors can be very different. One specific example is leukotriene B4 (LTB4) and 
leukotriene B4 receptor 1 (BLT1) expression. BLT1 is only found on effector memory 
CD8 T cells but not central memory CD8 T cells and the expression of BLT1 is 
essential in the recruitment of CD8 T cells into the lung and mediates airway 




inflammation and AHR (Miyahara et al., 2005a; Miyahara et al., 2005b; Tager et al., 
2003). It is also evident in humans that BLT1
+
 CD8 T cells are present in the 
asthmatic lung (Gelfand, 2006). However, whether and how the expression or lack of 
IFN-g would affect the expression of BLT1 is still unknown.  
In immunized mice as we have shown in previous chapters that recruitment of 
effector OT-I and IFN-γ
-/-
OT-I CD8 T cells was similar while effector IFN-γ
-/-
OT-I 
CD8 T cells were more efficiently recruited in naive mice. These seemingly 
contradictory findings might be related to the different microenvironment in the two 
different settings. While immunized mice would have rather established type II biased 
microenvironment before the transfer of CD8 T cells, the signals in naive mice must 
be much weaker if present at all. In the latter setting, a slight difference in adhesion 
molecule and chemokine receptor expression might result in a much greater 
difference in cell recruitment, while the effect of which might be easily overcome by 
the strong signals from the environment in immunized mice.  
 
As the recruitment of CD8 T cells into the lung was different, there was a possibility 
that the difference in eosinophil and neutrophil infiltration was the result of the 
difference in CD8 recruitment rather than the effect of IFN-γ. To address this question, 







cells) to enhance recruitment. We did not observe any significant difference in the 
recruitment rate with increased number of cells transferred and the cell infiltration in 
the BAL did not appear to be different either. Notably, the infiltration of cells 
especially eosinophils remained minimal even with 6×10
6
 CD8 T cell transfer. Thus, 




the difference we observed between the effect of OT-I and IFN-γ
-/-
OT-I CD8 T cells 
strongly depended on the intrinsic properties of the cells rather than the number of 
cells transferred or recruited into the lung. We also examined the effect of IFN-γ 
neutralization on the infiltration profile induced by OT-I CD8 T cells. No significant 
difference was found in the recruitment of CD8 T cells or the infiltration of 
granulocytes upon IFN-γ neutralization. This again proved that the different 
modulation effects of OT-I and IFN-γ
-/-
OT-I CD8 T cells were more dependent on the 
intrinsic properties of the two types of cells. 
 
We have argued that the pro-inflammatory property IFN-γ
-/-
OT-I CD8 T cells was not 
just due to the lack of IFN-γ production, but rather the changes induced by the lack of 
IFN-γ. The cytokine profile of effector IFN-γ
-/-
OT-I CD8 T cells indicated that the 
induction of inflammation was probably dependent on IL-13 and IL-17. IL-13 has 
been shown to play an important role in stimulating eosinophil infiltration via various 
mechanisms: IL-5 and eotaxin expression (Pope et al., 2001); promotion of eosinophil 
entry into the lung (Castilow et al., 2008); upregulation of various chemotactic 
factors(Wills-Karp, 2004). Indeed we observed an elevation of eotaxin in BAL of 
OVA-sensitized mice that received IFN-γ
-/-
OT-I CD8 T cells. Moreover, there is an 
emerging body of evidence that IL-17 contributes to eosinophil and neutrophil 
infiltration through the induction of a range of pro-inflammatory cytokines, 
chemokines and adhesion molecules (Cheung et al., 2008; Dragon et al., 2007; 
Kawaguchi et al., 2009; Moseley et al., 2003; Wong et al., 2001). Our data is 




consistent with these findings, demonstrating that in the absence of IFN-γ, the 
increased production of IL-17 from IFN-γ
-/-
OT-I CD8 T cells might have contributed 
to the promotion of cell infiltration especially neutrophils. It is still unclear in 
literature how reduced cytotoxicity could be involved in the regulation of 
inflammation. Le Gros’ group has showed that OT-I CD8 T cells inhibit Th2 
inflammation in a perforin-dependent manner (data not yet published) suggesting that 
cytotoxicity could also play a very important role in the inhibition of inflammation. 
OT-I CD8 T cells might exert their inhibitory effect through IFN-γ and their cytotoxic 
activity, both of which were lost or weakened in IFN-γ
-/-
OT-I CD8 T cells. 
 




CHAPTER 9: Final discussion 
 
9.1 Summary of findings 
The role of CD8 T cells in host defense against viruses and intracellular bacteria is 
well established (Heidema et al., 2007; Peterson et al., 2002; Sud et al., 2006; Uzonna 
et al., 2004) but their function in allergic disease is less clear. In this study, we aimed 
to investigate the regulatory role of CD8 T cells on the elicitation phase of an allergic 
response induced by OVA. We demonstrate that OT-I CD8 T cells display a Tc1-
biased phenotype after in vitro stimulation, expressing a high level of T-bet and 
predominantly producing IFN-γ. When these cells are transferred to immunized mice 
before OVA challenge, they are able to attenuate Th2 inflammation and mucus 
production. A robust Tc1-biased phenotype and IFN-γ production seem to be 
essential for CD8 T cell-mediated attenuation of eosinophilia and goblet cell 
hyperplasia as the same transfer experiment with stimulated effector IFN-γ
-/-
OT-I 
CD8 T cells fail to confer any protection. Indeed, not only do the effector CD8 T cells 
from IFN-γ
-/-
OT-I mice which predominantly produce IL-13 and IL-17 fail to 
ameliorate the hallmarks of allergic inflammation but rather potentiate both 
eosinophil and neutrophil infiltration. Adoptive transfer of effector IFN-γ
-/-
OT-I CD8 
T cells but not OT-I CD8 T cells into unimmunized mice induces a profound asthma-
like inflammation in response to allergen challenge, further highlighting the 
importance of IFN-γ in CD8-mediated regulation of allergy. Moreover, it also implies 
that effector IFN-γ
-/-
OT-I CD8 T cells seem to have pro-inflammatory nature which 




OT-I CD8 T cells do not possess. In line with previous studies, we also show that 
using IFN-γ neutralization antibody, the inhibitory effect of CD8 T cells is abrogated. 
However, no enhancement in inflammation is observed which implies that the pro-
inflammatory nature of IFN-γ
-/-
OT-I CD8 T cells is not solely dependent on the lack 
of IFN-γ production, but rather on the combined phenotype (biased IL-13, IL-17 





OT-I CD8 T cells have very different cytotoxic activity from OT-I 
CD8 T cells as well. At the naïve stage, IFN-γ
-/-
OT-I CD8 T cells are weaker killers 
when compared to OT-I CD8 T cells. Following in vitro stimulation, both types of 
cells have reduced cytotoxic activities and IFN-γ
-/-
OT-I CD8 T cells almost lose their 
cytotoxicity completely. There is not much evidence showing that cytotoxicity plays a 
role in the inhibitory effect of CD8 T cells in literature. However, Le Gros’ group  has 
demonstrated that perforin
-/-
OT-I CD8 T cells are not able to inhibit allergic 
inflammation which highlights a possible role of cytotoxicity in the regulatory role of 
CD8 T cells in asthma (unpublished data). Thus, in our study, the pro-inflammatory 
property of IFN-γ
-/-
OT-I CD8 T cells might be the combined effect of deficiency in 
IFN-γ, biased production of IL-13 and IL-17 and the loss of cytotoxicity.  
 
To look into the mechanisms underlying the inhibitory effect of CD8 T cells, we 
further demonstrate that both effector OT-I and IFN-γ
-/-
OT-I CD8 T cells increase the 








 lung DCs but only those from mice with OT-I CD8 T cell 
transfer could induce robust IFN-γ production by both naive and antigen-experienced 
CD4 T cells ex vivo. This finding indicates that altered DC function by IFN-γ-
producing CD8 T cells could be one of the mechanisms via which CD8 T cells 
promote a more Th1-permissive environment and thus inhibit Th2 allergic responses.  
 
9.2 Limitations of current study 
Inflammation vs AHR 
Most clinical studies of asthma take lung function as the gold standard to evaluate 
progression or improvement of disease while airway inflammation and mucus 
hypersecretion merely serve as tools in identifying asthma pathology. Improvement in 
AHR is the most important parameter in drug discovery and clinical trials. However, 
in our study, no significant change in AHR is observed following CD8 T cell transfer 
despite the effect on inflammation and mucus production. As we have discussed in 
chapter 5, the lack of improvement in AHR might be due to the increased infiltration 
of neutrophils which could also contribute to AHR although eosinophilia is attenuated. 
Thus, therapeutically, effector CD8 T cells might not be considered as a good 
candidate for they are not efficient in improving AHR. This study, indeed, focuses 
more on the mechanistic aspect of the modulating effect of CD8 T cells. By 
understanding the mechanisms, it would help in the discovery of drug targets in the 
intervention of asthma.  
 





We have identified antigen-specific effector CD8 T cells as negative modulators of 
allergic responses, but in the absence of IFN-γ they become positive inducers of 
inflammation. The lack of IFN-γ leads to dramatic changes in the CD8 T cells 
including the production of Th2 cytokine IL-13, Th17 cytokine IL-17 and reduced 
cytotoxic function on top of the deficiency in IFN-γ production, it is unclear whether 
one single change causes the pro-inflammatory behavior of effector IFN-γ
-/-
OT-I CD8 
T cells or whether it is the combined effect of all. Both IL-13 and IL-17 have been 
shown to play a role in inducing cell infiltration in asthma with IL-13 responsible for 
eosinophilia and mucus hypersecretion and IL-17 for neutrophilia. Reduced 
cytotoxicity can also contribute to the lack of suppression by CD8 T cells as 
demonstrated by Le Gros’ group. Thus, it might be interesting to find out which 
aspect of the changes in CD8 T cells is responsible for the lack of inhibition and the 
promotion of inflammation respectively.  
 
OVA vs natural allergen 
In this study, we have used OVA to induce allergic responses with the help of the 
adjuvant alum. However, it is somewhat an artificial system as OVA is not a natural 
allergen and adjuvant is needed to induce a robust response. Natural allergens like 
HDM and cockroach are now quite commonly employed by researchers to establish 
more physiological and clinically relevant models of asthma. Different allergens have 
different properties and potencies in inducing an allergic response which may involve 
different players and mechanisms and a simple OVA model would not be able to 




represent all. However, due to the limitations of available tools and transgenic mice, 
we were not able to investigate the role of CD8 T cells in asthma models using 
natural allergens.  
 
 9.3 The paradox of CD8 T cells and IFN-γ in asthma 
The role of CD8 T cells in asthma has been a constant source of discussion for they 
seem to have many faces in the pathogenesis and regulation of the disease. While it is 
evident that Tc1 cells alleviate and Tc2 cells exacerbate asthma, the exact mechanism 
has yet to be elucidated. It is relatively well recognized that the detrimental effect of 
CD8 T cells relies on the biased Tc2 phenotype and these cells are more commonly 
found in severe asthma. Indeed, it was shown that circulating CD8 T cells but not 
CD4 T cells were the ones that were most activated in severe asthma patients 
(Tsitsiou et al., 2011). If skewed towards Tc1, CD8 T cells can attenuate asthma via 
mechanisms involving IFN-γ as showed in this study and a few previous studies. 
However, the role of IFN-γ itself in asthma is quite complex. While there are reports 
showing that IFN-γ could act on airway epithelium to inhibit asthma pathology 
(Mitchell et al., 2011), eosinophil differentiation (de Bruin et al., 2010) and play a 
crucial role in the inhibitory effect of CD8 T cells, there is also evidence showing that 
an increased number of IFN-γ-expressing cells could be found in severe asthma 
patients (Shannon et al., 2008) and that IFN-γ could elevate AHR in severe asthma 
models (Kobayashi et al., 2011). Moreover, IFN-γ in cooperation with IL-27 could 
induce steroid-resistant AHR (Li et al., 2010). It appears that the exact role of IFN-γ 




in asthma depends on the severity of the disease and the cells that it acts on. This 
might explain the limited success of using recombinant IFN-γ in treating asthma 
(Boguniewicz et al., 1995). If IFN-γ is introduced at the right time and in the right 
environment, it does have the potential for inhibiting Th2 inflammation. As opposed 
to cases with severe asthma, in our study, there was no evidence showing that the 
pathology induced by OVA involves the role of IFN-γ as this cytokine was not 
detected in the BAL. Thus, it is not surprising that the exogenous IFN-γ introduced 
into the OVA-immunized and challenged mice played a beneficial role against Th2 
responses. 
 
We have shown that CD8-derived IFN-γ is important in the inhibitory effect of CD8 
T cells on asthma, probably through skewing the Th1 priming potential of DCs. There 
are studies showing that a Th1 response can counterbalance Th2-induced 
inflammation, mucus production and AHR without inducing significant pathology 
related to Th1 cells and that Th1 cells do not induce mucus hypersecretion even 
though they may induce some inflammation (Cohn et al., 1997; Cohn et al., 1999; 
Huang et al., 2001). However, it is also shown in other studies that Th1 cells fail to 
counterbalance Th2-induced AHR but rather potentiate inflammation (Hansen et al., 
1999a) and cooperation between Th1 and Th2 exacerbates airway inflammation 
(Randolph et al., 1999b). As the complicated role of IFN-γ, the role of IFN-γ-
producing Th1 cells is also highly dependent on circumstances. When introduced or 
induced in systems with established Th2 responses and persist concurrently with Th2 
cells, Th1 cells seem to do more harm than good.  However, if a Th1 response is 




induced at the expense of Th2 response, ie, the microenvironment favors a Th1 
response and as a result prevents a Th2 response, the overall outcome is likely to be 
therapeutic. In our study, CD8 T cell transfer results in the modification of DC 
function, creating a Th1-permissive environment and thus attenuating Th2 
inflammation. This further proves that when a Th1 response is induced in the right 
way, it could be beneficial as proposed in the hygiene hypothesis. The fact that CD8 
T cells are able to affect DC function also highlights the possibility of manipulating 
CD8 T cells so that they could direct DCs towards the desired function which would 
have maximum benefit for asthma.  
 
9.4 Current therapy for asthma  
In a nutshell, asthma is a multifactorial, multigenic disease with no prevention or 
absolute cures to date. The complex code of multiple genetic and environmental 
factors that leads to asthma is beyond the interpretive capacity of current technology 
such that no single treatment is able to terminate asthma manifestation once and for 
all. Over decades, agents targeting at relief of asthma symptoms have been the major 
available drugs in the market. However, these drugs are usually short-acting with no 
long-term benefit. Recently, the development of cytokine/anti-cytokine therapy has 
become more and more active which also achieved certain level of protection, 
although still far from a cure. Meanwhile, immunotherapy research has been on the 
rise, aiming to find a solution with more effective and long-term protection. 
 





Targeting the symptoms: Anti-inflammatory therapy 
As inflammation is one of the major manifestations of asthma and it can also lead to 
the development of airway hyperreactivity and airway obstruction, anti-inflammatory 
drugs are of the most common asthma treatments available. Inhaled corticosteroid 
(ICS) is the most commonly used anti-inflammatory drug thus far and remains the 
cornerstone of anti-inflammatory therapy (Rottier and Duiverman, 2009). ICS binds 
to glucocorticoid receptor in the cytoplasm and translocates to the nucleus, leading to 
changes in gene transcription. The desired effect of reducing the synthesis of pro-
inflammatory cytokines, chemokines and adhesion molecules also comes with a price: 
systemic side effect may result from changed gene transcription (Barnes, 2006). 
Nevertheless, ICS remain the mainstream of asthma therapy, especially in 
conjunction with β2-adrenoceptor agonists which are bronchodilators for fast relief 
(Holgate and Polosa, 2008). While ICS have relatively broad targets, leukotriene 
receptor antagonists (LTRA) are the first anti-inflammatory drugs targeting a specific 
mediator. As leukotrienes are potent inducers of inflammation, neutralizing 
leukotrienes is believed to be able to alleviate asthma symptoms. However, the 
effectiveness of LTRA for asthma is still under review (Rottier and Duiverman, 2009).  
 
Targeting the symptoms: Cytokine/anti-cytokine therapy  
The fact that cytokines produced by T cells and some innate cells play a major role in 
inducing asthma pathology leads to the development of cytokine/anti-cytokine 
therapy targeting at one or more of the cytokines that cause asthma (Hansbro et al., 




2011). Briefly, IL-4, IL5, IL-13, IL-17, TSLP, IL-25 and IL-33 are the major 
cytokines contributing to asthma symptoms and drugs targeting at the neutralization 
of these cytokines or blocking their signaling are being tested in clinical trials. Anti-
IL-4 neutralizing antibody (pascolizumab) (Hart et al., 2002), soluble IL-4Rα (Borish 
et al., 2001), monoclonal anti-IL-4Rα antibody (AMG317) (Corren et al., 2010), anti-
IL-5 mAbs (mepolizumab (Flood-Page et al., 2007) or SCH55700 (Kips et al., 2003)) 
and IL-13 neutralizing antibodies (IMA-638, CAT-354 and AMG 317) (Singh et al., 
2010) offer various degrees of protection and are already or soon to be available on 
market. Drugs targeting IL-17, TSLP, IL-25 and IL-33 are also emerging with strong 
support from mouse experiments. Due to the broad range of cytokines involved in 
asthma, targeting one single cytokine may not be sufficient to suppress the multiple 
inflammatory processes in asthma, but rather alleviating selective symptoms related 
to that specific cytokine.  
 
Targeting the root: Immunotherapy 
The shortcomings of therapies targeting the symptoms of asthma led researchers and 
drug companies to put more effort into developing drugs and therapies that could 
offer long-lasting protection or better still, a cure. Immunotherapy aims to suppress 
over-reactive Th2 response in various ways: by tilting the immune system towards a 
Th1 response; by inducing anergy and tolerance to turn off the response; and by 
promoting an immune-suppressive T cell response. While therapies trying to initiate a 
shift from Th2 to Th1 response had limited success in clinical trials (Arkwright and 
David, 2001; Vargas et al., 2004), DCs and Tregs which could tune down the overall 




immune response are becoming popular targets in immunotherapy development. 
Therapies promoting the generation of Treg cells which produce IL-10 and TGF-β 
and thus suppress the Th2 response have been tested for efficacy and safety with 
further studies required for refining the strategies (Akdis and Akdis, 2007; O'Hehir et 
al., 2009; Rolland et al., 2009; Thorburn and Hansbro, 2010). DCs can also be 
modified so that they could reset the balance of immune response in favor of Treg 
cell function which leads to a more long-lasting suppressive effect on asthma (Kool 
and Lambrecht, 2007). We have shown that CD8 T cells are able to modify DC 
function, skewing their differentiation capacity.  It highlights the possibility that CD8 
T cells can be used to change DC function. 
  
9.5 Future studies 
The unique feature of IFN-γ
-/-
OT-I CD8 T cells 
Other than the expected deficiency in IFN-γ production, IFN-γ
-/-
OT-I CD8 T cells 
have unique features including their biased production of IL-13 and IL-17 as well as 
reduced cytotoxicity. It would be interesting to find out which aspect of the changes 
is responsible for the pathology induced by these cells. While the role of IL-13 and 
IL-17 in inflammation is quite well established and neutralization of IL-13 and IL-17 
can be carried out to identify the contribution of these two cytokines, the role of 
cytotoxicity is of particular interest.  Perforin
-/-
OT-I mice can be generated and 
similar transfer experiment can be carried out to study the role of cytotoxicity. As 
IFN-γ
-/-
OT-I CD8 T cells have quite dramatic change in their phenotype, it would be 




worth determining the phenotype of Perforin
-/-
OT-I CD8 T cells as well. The 
suppressive effect of CD8 T cells might not be solely dependent on IFN-γ; 
cytotoxicity might also play a role. Whether cytotoxicity is involved in the 
modification of DC function can also be investigated and would add on to our current 
understanding of the underlying mechanisms.  
 
Memory CD8 T cells in asthma 
Effector CD8 T cells are potent in inducing inflammation as suggested by Gelfand’s 
group while memory CD8 T cells are not able to restore the abolished inflammation 
due to the deficiency in endogenous CD8 T cells. Although our study suggests that 
exogenous effector CD8 T cells attenuate eosinophilia established in mice with 
functional endogenous CD8 T cells, these cells also induce significant Th1 
inflammation most notably neutrophilia. The overall effect of effector CD8 T cell 
transfer is not satisfactory enough for they are not able to significantly modify AHR. 
Thus, memory cells might be a better candidate for tuning down Th2 allergic 
responses without exaggerating Th1 inflammation. As memory cells can be 
efficiently generated in the presence of IL-15 as opposed to IL-2 for effector cells 
(Calarota et al., 2008; Ott et al., 2003), PMA and ionomycin stimulation can be 
replaced by stimulation of antigen-pulsed CD8 T cells in the presence of IL-15. IL-7 
can also be added to the culture as it has been shown to boost memory cell generation 
and enhance memory (Purton et al., 2008). We can then transfer the generated 
memory cells to mice before sensitization or challenge to investigate their regulatory 




function. Other than in vitro generation of memory cells, natural memory cells 
(CD44
+
 cells) can also be isolated and used for adoptive transfer.  
 
Lung function and T cell differentiation 
Although we have shown that lung DC functions were modified towards Th1 priming 
by the transferred CD8 T cells, the change of DC phenotype in terms of surface 
molecule expression was not discussed. TLRs, Notch ligands and Notch receptor are 
all expressed on DCs and their signaling was shown to be important in the induction 
of DC cytokine production and thus the differentiation of T cells (Bugeon et al., 2008; 
Ito et al., 2009; Kunkel and Ito, 2009). Notch signaling is very complex involving two 
main different families of ligands (Delta-like and Jagged) and four different receptors. 
The engagement of different ligands and receptors results in different signaling 
pathways and different cytokine production profiles (Bugeon et al., 2008; Dallman et 
al., 2005). Moreover, TLR signaling (TLR9 for instance) can lead to DC cytokine 
production through the effect on Notch signaling (Ito et al., 2009). In our study, the 
modification of the Notch signaling pathway might be one of the mechanisms via 
which CD8 T cells regulate DC priming function. Besides the effect on DCs, Notch 
signaling can also directly affect T cell differentiation and cytokine production 
(Dallman et al., 2005). Thus, it would be rather interesting to find out whether the 
expressions of Notch receptors, Notch ligands and TLRs were altered on DC surface 
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